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ABSTRACT 
 
Introduction: Human immunodeficiency virus (HIV) is continuously rewriting 
medical history as one of the diseases affecting humankind. Current treatments 
available for HIV, namely antiretrovirals (ARVs), do not completely eradicate the 
virus from the body, leading to life time commitment. Many ARVs suffer from high 
toxicities and unpleasant side effects; as a result many patients do not adhere to 
the treatment. Nanoparticles (NPs) used as drug delivery systems (DDS) hold 
tremendous potential, since they can easily protect the drug from external 
environment and enter the human cells to deliver drugs. Therefore, the main 
objective of this work was to load two ARVs, namely lamivudine (LAM) and 
efavirenz (EFV), into a biodegradable, biocompatible poly(epsilon-caprolactone) 
(PCL) polymer based NPs. LAM is a hydrophilic drug suffering from low half life of 
5 to 7 hours and many unpleasant side effects. EFV is a hydrophobic drug 
suffering from low aqueous solubility (4 µg/ml), which leads to a limited oral 
absorption and low bioavailability (40-45%). 
Method: The effect of various process parameters, including the solvents, namely 
ethyl acetate (EA), dichloromethane (DCM), their mixtures and excipients, namely 
lactose or trehalose were assessed on the preparation. The hydrophilic (LAM) and 
hydrophobic (EFV) ARVs were nano-encapsulated into PCL polymer via the 
double emulsion spray drying method. The prepared drug-loaded PCL NPs were 
evaluated by dynamic light scattering (DLS), fourier transform infrared 
spectroscopy (FTIR), ultraviolet (UV) spectroscopy, differential scanning 
calorimetry (DSC), thermogravimetry analysis (TGA), X-ray diffraction (XRD). In 
addition, the in vitro drug release was also studied. 
Results: Small spherical NPs with size of less than 300 nm were obtained, with 
good PDI when EA and lactose were used in the preparation for both drugs. 
However DCM presented size of more than 300 nm with poor PDI, irrespectively of 
whether lactose or trehalose was used in the preparation. Some of the NPs 
prepared with trehalose presented the formation of rods. The presence of LAM 
and EFV into PCL NPs were confirmed by FTIR. UV spectroscopy showed the 
encapsulation efficiency ranging from 68.4% to 77.82 % for LAM and more than 
v 
90% for EFV. XRD and DSC showed that it was possible to prepare amorphous 
materials with double emulsion spray dried method for both drugs. Residual 
moisture of less than 5 % was observed for both drugs. Typical release behaviour 
was observed for more than five days for EFV and 2 days for LAM. 
Conclusion: These results indicated that LAM or EFV nano-encapsulated within 
PCL NPs is a promising carrier for controlled delivery, furthermore no changes in 
the chemical or nature of the drug were observed. Thus these can be an efficient 
way of increasing patient compliance particularly in sub-Saharan Africa in the near 
future. 
Keywords: Human immunodeficiency virus, Nanoparticles, Poly(epsilon-
caprolactone), Lamivudine, Efavirenz, Drug delivery 
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CHAPTER 1:  
 INTRODUCTION 
 
 
1.1 General background 
Poverty related diseases (PRDs) which are acute mostly in countries described as 
“low income” or “developing” have posed significant challenges to human society as 
shown in Fig. 1.1 (Look et al., 2010). Most epidemic PRDs such as tuberculosis 
(TB), human immunodeficiency virus associated/ acquired immune deficiency 
syndrome (HIV/AIDS) and malaria show a noticeably higher prevalence in poor 
countries. HIV/AIDS in fact is continuously re-writing medical history as one of the 
humankind deadliest diseases (Gupta and Jain, 2010). According to the latest 
reports on the HIV/AIDS pandemic, an estimated 33.2 million people are living with 
HIV, with 25 million lives claimed since its discovery in 1981 due to AIDS (Look et 
al., 2010; Gupta and Jain, 2010; Wong et al., 2010; Neves et al., 2010). The sub-
Saharan Africa accounts for the highest population and South Africa displays an 
excessive number of the global HIV burden with an estimate of approximately 22.5 
million (Wong et al., 2010) and 5.6 million cases (UNAIDS, 2011); respectively. 
These regions continue to be the major victims of HIV, even though signs of decline 
in the case of new infection have been observed in developed countries due to better 
treatment, prevention and HIV/AIDS awareness (Wong et al., 2010; Kim and Read, 
2010) . 
Based on the insightful information gained about HIV/AIDS replication cycle, 
treatment options are available known as ARVs (Clercq, 2009). The first drug was 
approved by the United States Food and Drug Administration (US-FDA) in 1987 
followed by total approval of more than 25 ARVs to date, some of which are also 
available in fixed dose combination (FDC) (Wong et al., 2010; Mamo et al., 2010 ). 
Table 1.1 summarizes different families of ARVs that are used to treat HIV/AIDS and 
novel drug candidates under clinical evaluation. The highly active antiretroviral 
2 
treatment (HAART), which is the current clinical therapy for HIV/AIDS, consists of at 
least three ARVs (Mallipeddi and Rohan, 2010) 
 
Figure 1.1: (A) Burden of infectious disease in low income countries. Infectious 
disease burden distribution by income group, as measured by disability- adjusted life 
years (DALYs). A DALY measures years of healthy life lost due to premature 
mortality. Income levels are based on the gross national income per capita, and are 
grouped as low income (<US$825), middle income (US$826-US$10,065), and high 
income (> US$10,066) nations. (B) Mortality due to infectious diseases in low income 
nations (Look et al., 2010) 
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Table 1.1: Representation of ARVs and new drug candidate under clinical evaluation (Sosnik et al., 2009) 
Drug family Drug Commercial name (company) FDA 
approval 
Dosage forms Adult dose Pediatric dose 
Nucleoside 
reverse 
transcriptase 
inhibitors 
(NRTIs) 
Zidovudine 
(AZT) 
 
Didanosine 
 
 
 
 
Zalcitabine⁎ 
 
Stavudine 
 
 
Lamivudine 
 
 
Abacavir 
 
Retrovir ® (GlaxoSmithKline) 
 
 
Videx ® (Bristol Myers Squibb) 
 
 
 
 
Hivid ® (Hoffmann-La Roche) 
 
Zerit ® (Bristol Myers Squibb) 
 
 
Epivir ® (GlaxoSmithKline) 
 
 
Ziagen® ABC (GlaxoSmithKline) 
 
1987 
 
 
1991 
 
 
 
 
1992  
 
1994  
 
 
1995 
 
 
1998 
 
Tablets (300mg), capsules 
(100 mg), syrup (10 mg/mL). 
 
Capsules (125, 200, 250,400 
mg), oral solution(powder —2 
g), oralsuspension (pediatric 
powder—2 g), and tablets (25, 
50,100, 150 mg). 
Tablets (0.375, 0.750 mg)   
 
Capsules (15, 20, 30, 40 mg) 
and oral solution (1 mg/mL) 
 
Tablets (150, 300 mg) and 
oral solution (10 mg/mL) 
 
Tablets (300 mg) and oral 
solution (20 mg/mL) 
 
600 mg/day 
(2 doses) 
 
400 mg/day 
(1 dose) 
 
 
 
2.25 mg/day 
(3 doses) 
80 mg/day 
(1 or 2 doses) 
 
300 mg/day 
(1 or 2 doses) 
 
600 mg/day 
(1 or 2 doses) 
160 mg/m2 every 8 h 
 
 
120 mg/m2 twice 
daily 
 
 
 
 
Na 
 
 
1 mg/kg/dose every 
12 h 
 
4 mg/kg twice daily 
(up to a maximum of 
150 mg twice a day) 
8 mg/kg twice daily 
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Emtricitabine 
 
 
Emtriva ® (Gilead Sciences) 
 
 
2003 
 
Capsules (200 mg) and oral 
solution (10 mg/mL) 
 
 
Capsule: 200 
mg/day  
Oral solution: 
240 mg/day 
(1 dose) 
(maximum of 300 mg 
twice 
daily) 
 
 
6 mg/kg, maximum of 
240 mg (24 mL) once 
daily 
Nucleotide 
reverse 
transcriptase 
inhibitors 
(nRTIs) 
Tenofovir Viread ® (Gilead Sciences) 2001 Tablets (300 mg) 300 mg/day 
(1 dose) 
Na 
Non-
nucleoside 
reverse 
transcriptase 
inhibitors 
(NNRTIs) 
Nevirapine 
 
 
 
 
Delavirdine 
 
Efavirenz⁎ 
 
 
Viramune ® (Boehringer 
Ingelheim) 
 
 
 
Rescriptor ® Sustiva.™, 
Stocrin.™ (Pﬁzer) 
Sustiva ® (Boehringer 
Ingelheim) 
 
1996 
 
 
 
 
1997 
 
1998 
 
 
Tablets (200 mg) and oral 
suspension (10 mg/mL) 
 
 
 
Tablets (100 mg) 
 
Capsules (50, 100, 200 mg), 
tablets (300, 600 mg) and 
oral solution (30 mg/ml) 
First 14 days: 
200 mg/day 
Alter 14 days: 
400 mg/day 
(2 doses) 
1200 mg/day 
(3 doses) 
600 mg/day 
(1 dose) 
 
 
150 mg/m 2 once 
daily for 14 days 
followed by 150 
mg/m 2 twice daily 
 
 
Na 
 
10 kg b15 kg (200 
mg), 15 kg b20 kg 
(250 mg), 20 kgb25 
kg (300 mg), 25 
5 
 
 
 
 
Etravirine 
 
 
 
 
 
Intelence ® (Tibotec, J&J) 
 
 
 
 
2008 
 
 
 
 
Tablets (100 mg) 
 
 
 
400 mg/day 
(2 doses) 
kgb32.5 kg (350 mg), 
2.5 kgb40 kg (400 
mg), at least 40 kg 
(600 mg) once daily 
 
Na 
Protease 
inhibitors 
(PIs) 
Saquinavir   
 
Indinavir 
 
Ritonavir 
 
 
Lopinavir 
Nelﬁnavir 
 
Amprenavir 
 
 
 
Invirase ® (Hoffmann-La Roche) 
 
Crixivan ® (Merck & Co.) 
 
Norvir ® (Abbott Labs) 
 
 
Aluviran ® (Abbott Labs) 
Viracept ® (Pﬁzer) 
 
Agenerase ® (GlaxoSmithKline) 
1995 
 
1996 
 
1996 
 
 
1997 
1997 
 
1999 
Capsules (200 mg) and tablets 
(500 mg). 
Capsules (100, 200, 300, 
400 mg). 
Soft capsules (100 mg) 
and oral solution 
(600 mg/ 7.5 mL). 
Na 
Oral powder (50 mg/g) and 
tablets (250 and 625 mg) 
Capsules (50 mg) and oral 
solution (15 mg/mL) 
2000 mg/day 
(2 doses) 
2400 mg/day 
(3 doses) 
1200 mg/day 
(2 doses) 
 
Na 
2500 mg/day 
(2 or 3 doses) 
2400 mg/day 
(2 doses —24 
capsules×dos
e) 
Na 
 
Na 
 
350 to 400 mg/m2 
twice daily, not to 
exceed 600 mg twice 
daily 
 
Na 
45 to 55 mg/kg twice 
daily or 25 to 35 
mg/kg three times 
daily 20 mg/kg twice 
daily or 15 mg/kg 3 
times daily (to a 
maximum daily dose 
of 2400mg) 
 Fosamprenai Lexiva ® (GlaxoSmithKline) 2003 Tablets (700 mg) and oral 2800 mg/day 30 mg/kg twice daily, 
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Atazanavir 
 
Tipranavir 
 
Darunavir 
 
Reyataz ® (Bristol Myers Squibb) 
 
Aptivus ® (Boehringer Ingelheim) 
 
Prezista ® (Tibotec, J&J) 
 
2003 
 
2005 
 
2006   
suspension (50 mg/mL) 
Capsules (100, 150, 200,  
300 mg) 
Capsules (250 mg) and oral 
solution (100 mg/mL) 
Tablets (75, 300, 400, 
600 mg) 
(2 doses) 
400 mg/day 
(1 dose) 
1000 mg/day 
(2 doses) 
1200 mg/day 
(1 or 2 doses) 
not to 
exceed the adult 
dose. 
15 kg b20 kg 8.5 
mg/kg once daily 
 
14 mg/kg twice daily, 
maximum dose 500 
mg. 
 
Na 
Viral 
fusion/entry 
inhibitors 
Enfuvirtide 
 
 
Maraviroc 
 
Vicriviroc 
Fuzeon ® (Hoffmann-La Roche) 
 
 
Selzentry ® (Pﬁzer) 
 
Schering-Plough 
2003 
 
 
2007 
 
Phase III 
Powder (lyophilized) for 
injectable solution (90 mg/mL) 
 
Tablets (150, 300 mg) 
 
Tablets (30 mg) 
180 mg/day 
(2 doses) 
 
1200 mg/day 
(2 doses) 
30 mg/day 
6 to 16 years of age, 
2 mg/kg twice daily. 
Maximum dose 90 
mg twice daily 
Na 
 
Na 
Integrase 
inhibitors 
Raltegravir 
 
Elvitegravir 
Isentress ® or MK-0518 (Merck 
& Co.) 
Gilead Sciences 
2007 
 
Phase III 
Tablets (400 mg) 
 
Na 
800 mg/day 
(2 doses) 
150 mg/day 
Na 
 
Na 
Maturation 
inhibitor 
Bevirimat Panacos Pharmaceuticals Phase II Tablets and oral solution 
(concentration Na) 
600 mg/day Na 
7 
Fixed Dose 
Combinatios 
(FDC) 
Lamivudine/ 
Zidovudine 
Abacavir/ 
lamivudine/ 
zidovudine 
Lopinavir/ 
ritonavir 
 
 
Tenofovir/ 
emtricitabine 
Combivir ® (GlaxoSmithKline) 
 
Trizivir ® (GlaxoSmithKline) 
 
 
Kaletra ® (Abbott Labs) 
 
 
 
Truvada ® (Gilead Sciences) 
1997 
 
2000 
 
 
2000 
 
 
 
2004 
Tablets (150, 300 mg) 
 
Tablets (150, 300 mg) 
 
 
Tablets (50, 200 mg), oral 
solution (80 mg/mL, 20 mg/ 
mL) 
 
Tablets (200, 300 mg) 
300 and 600 
mg (2 doses) 
300 to 600 
mg (2 doses)   
 
200 to 800 
mg (1 or 2 
doses) 
 
 
200 to 300 
mg (1 dose) 
**** 
 
**** 
 
 
7 kg b15 kg  (12/3 
mg/kg), 
15 kg b40 kg  (10/2.5 
mg/ 
kg),  b40 kg  
(400/100 mg) 
twice daily 
****A ﬁ xed-dose tablet cannot be dose adjusted for the pediatric population. 
Na: not available.
 8 
It is considered as one of the most important advances in the field of HIV/AIDS 
(Sharma and Garg, 2010). HAART has dramatically changed the clinical course of 
HIV/AIDS infection by suppressing the virus, and has led to a great improvement by 
extending the life of the HIV/AIDS infected patients. In this context, it has turned 
HIV/AIDS from a fatal disease to a manageable chronic condition (Delaney, 2006) 
HAART is a lifetime obligation that only used to control the viral load of the infected 
patients; any non-adherence leads to rebound of viral replication. According to 
epidemiological studies, adherence levels below 95% (e.g. no more than two doses 
missed monthly in a twice-a-day regime) tend to diminish the chances of 
therapeutic success approximately to 50% (Shah, 2007). Unfortunately even good 
adherence to HAART regime does not lead to complete eradication of the virus in 
the body, and as a result HIV/AIDS is incurable (Mamo et al., 2010 ). The challenge 
facing these ARVs when administered orally is that they undergo extensive 
gastrointestinal (GI) degradation and first pass metabolism, which has been 
reported to be a leading factor for the observed low bioavailability (Sosnik et al., 
2009). In addition administration of HAART regimen in high doses contributes to 
poor patient compliance. Therapeutic success relies not only on the affordability to 
medications but more importantly on the patient compliance. Thus there is an 
urgent need for new drug delivery system (DDS) that can improve some of the 
HIV/AIDS treatment challenges, with the aim to increasing or improving patient 
compliance. 
Nanotechnology research and development involves the design of novel structures 
within the nanometer range. In this size range, researchers can nano-encapsulate 
drugs into materials by changing their size, shape and surface compositions 
(Sosnik et al., 2010). This technology can advance the field of medicine due to high 
surface area to volume ratios and several other unique properties (Husseini and 
Pitt, 2008; Mishra et al., 2010). Moreover contributions from various fields has put 
forward techniques for the preparation of new DDS in order to ensure effectiveness 
with minimal side effects (Husseini and Pitt, 2008). 
The aim of this project was to nano-encapsulate two existing ARVs, namely LAM 
(belonging to NRTIs) and EFV (belonging to NNRTIs) into PCL polymer, as shown 
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in Fig.1.2, using double emulsion spray drying technique. The basis of choosing 
LAM and EFV as model drugs is that they are the current drugs used in South 
Africa for first line HIV/AIDS treatment. 
 
  
A)                                                                                                                   B) 
                                                                                                                                                                                                                                      
                O 
 O      ( CH2)5         C 
    n 
 
 
 
(C) 
Figure 1.2: Chemical structure of A) EFV, B) LAM, and C) PCL 
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1.2 Hypotheses 
The nano-encapsulation of LAM and EFV into polymeric material can protect these 
drugs from physiological conditions. Controlled and steady drug release can also be 
achieved as the polymer degrades, resulting in the reduced number of 
administration schedules, with reduced dosing frequency, increased bioavailability 
due to the increased surface area of the nano-encapsulated drug.     
1.3 Objectives of the study 
 To nano-encapsulate LAM and EFV into PCL polymer NPs using the double 
emulsion spray drying technique. 
 Characterise NPs using, 
i. Dynamic light scattering (DLS), for particle size, particle size distribution and 
zeta potential 
ii. Fourier transform infrared (FTIR), for structural composition 
iii. Scanning electron microscopy (SEM), for surface morphology 
iv. X-ray diffraction (XRD), for amorphousness and crystallinity  
v. Differential scanning calorimetry (DSC) and thermogravimetric analysis 
(TGA), for degree of melting point, crystallinity and thermal stability. 
 Study in vitro release profiles of these particles using ultraviolet (UV) 
spectrophotometry. 
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1.4 Justification 
This project was to develop nano-encapsulation method of two existing ARVs, 
namely LAM and EFV into PCL polymer using a double emulsion spray drying 
technique in order to change degree of crystallinity for both drugs, and improve 
drug-release properties. Amorphous solid drugs are characterized by no long-range 
of molecular packing and useful properties include higher solubility and dissolution 
rate than the crystalline form (Yu, 2001). If the crystallinity of these two drugs could 
be decreased this could reduce the intervariable bioavailability associated with 
crystalline drugs and their associated polymorphisms. Controlled release might 
reduce dose frequency and significant side effects associated with ARVs as the 
polymer degrade. The intended route of administration of these NPs will be orally 
since it’s easy as compared with other route of administration. These would 
ultimately lead to better patient compliance. 
 
1.5 Method and polymer selection 
1.5.1 Methods of producing polymeric NPs 
Encapsulation is a process of enclosing one substance (a solid, liquid and gas) 
within another material, which in turn protect them from the external environment 
(Ghosh, 2006). The substance that is encapsulated into another material is usually 
called the core material, an active ingredient or internal phase. The material 
encapsulating the core is mainly referred to as the membrane, shell or wall material 
(Jyothi et al., 2010). If the material being encapsulated results in a size less than 1 
μm, the process is called nano-encapsulation, conversely above 1 μm the process 
is referred to as micro-encapsulation. Substances that are usually encapsulated 
include drugs, foods, oils and sensitive materials (Jyothi et al., 2010). Many 
researchers use polymers to form the shell (Rao and Geckeler, 2011). The choice 
of the polymer depends on the physicochemical properties of the core, process of 
making nano or micro-encapsulation, and the desired properties of the final product. 
Some advantages of nano or micro-encapsulation include (Jyothi et al., 2010): 
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 to protect the sensitive material (e.g. drug) from the external environment 
 to obtain the controlled release of the drug as the polymer degrades 
 deliver the drug to a specific location 
 to make handling of the material much easier and 
 to avoid side effects like gastric irritation of the drug 
Nano-encapsulation using polymeric materials can be achieved by dispersion of the 
preformed polymers into suitable solvents (Soppimath et al., 2001; Rao and 
Geckeler, 2011). The previously studied method includes polymerization of 
monomers. However main drawbacks of the polymerization methods are the 
presence of residual sub-products that impart toxicity in the final product, 
probabilities of drug inhibitions due to interactions, or cross reactions with the drug 
with the activated monomers and H+ ions present during polymerization that 
requires washing of the final product (Astete, 2005). As a result dispersion of the 
preformed polymer into suitable solvent is preferred over polymerization methods, 
and these include: 
 solvent evaporation 
 nanoprecitation 
 salting-out 
 dialysis 
 supercritical fluid technology 
Details of the methods are covered in the review papers by Rao and Geckeler, 
2011 and Soppimath et al., 2001. Each synthetic method has its own advantages 
and disadvantages. For the present study solvent evaporation method was used as 
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a method of choice, since it allows various solvents to be used, and both hydrophilic 
and hydrophobic drugs can be nano-encapsulated using the method. 
1.5.2 Solvent evaporation method 
The solvent evaporation method has been extensively used in the preparation of 
NPs using various polymers (Jain, 2000). Two main strategies are being used for 
the preparations of emulsions, namely single emulsion i.e. oil-in-water (o/w) and 
double emulsion i.e. water- in-oil-in-water (w/o/w) (Rao and Geckeler, 2011). In 
these two strategies, the polymer is dissolved in a suitable organic solvent, such as 
dichloromethane (DCM), chloroform or ethyl acetate (EA) etc. The resultant solution 
is then emulsified in an aqueous continuous phase containing stabilizers followed 
by homogenization (high speed or pressure) or ultrasonication to form o/w 
emulsion. The detailed procedure for w/o/w method is presented in Fig 1.3, in which 
the resulting solution from the first step (o/w) is transferred into another aqueous 
phase containing surfactants, followed by homogenization to obtain w/o/w 
emulsion. 
 
Figure 1.3: Schematic representation of w/o/w double method. (Rao and Geckeler, 
2011) 
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1.5.3 Spray drying 
Spray drying is a widely applied technique to convert an emulsion, suspension or 
dispersion to a dry state by atomizing the product and passing it through a hot 
drying gas (Buchi Labortechnik AG, 1997–2002; Cal and Sollohub, 2010). It is a 
well-established method currently employed in a number of industries e.g. food, 
cosmetic and pharmaceutical industries. A typical spray drying process consists of 
three steps that involve atomization of the liquid (emulsion, suspension or 
dispersion), drying of the liquid and particle collection. Initially, the liquid feed is 
directed through an atomizer device that put the feed in contact with the hot drying 
gas, and produces fine droplets into the drying chamber (Cal and Sollohub, 2010). 
Atomizers may vary depending on the applications, and this includes rotary 
atomizers, hydraulic nozzles, pneumatic nozzles and ultrasonic nozzles. The hot 
drying gas is normally the atmospheric air, but other gases like nitrogen or inert 
gases can be used, however these gases are normally avoided as they are 
expensive and require installation (Mujumdar, 2006; Cal and Sollohub, 2010). In 
general the contact time of the hot drying gas and spray droplet is only a few 
seconds, as a result the dried particle never reaches the temperature of the drying 
air. This property makes the spray dryer to be suitable process for thermally 
sensitive substances (Cal and Sollohub, 2010). The final product is then 
continuously discharged from the hot drying chamber and recovered from the 
cyclone or filter bag. Figure.1.4 presents the main components of a spray dryer. 
Some advantages of spray drying compared to freeze dried and jet milled products 
include, 
 one step process to produce dry particles directly from liquid formulation 
 control of particle shape, morphology and density depending on process 
parameters 
 process simplicity, cost effectiveness and scale-up abilityhighly dispersible and 
spherical particles with narrow particle size distribution. 
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Figure 1.4: Schematic representations of main components for the mini spray dryer 
B-290 (Buchi Labortechnik AG, 1997–2002). 
1. Two-fluid nozzle, operated by compressed air to disperse the solution into fine 
droplets 
2. Electric heating of the drying medium 
3. Spray cylinder for drying the droplets to solid particles 
4. Separation of the particles in the cyclone 
5. Outlet filter to remove fine particles 
6. Aspirator for generating the flow 
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1.5.4 Selection of polymer  
A wide variety of synthetic and natural polymers are available in the market for the 
production of NPs (Rao and Geckeler, 2011). For drug delivery applications US-
FDA biodegradable and biocompatible are preferred candidate over other polymers. 
Natural polymers have been employed for drug delivery systems. However these 
polymers are more restricted due to their uncertainty in purity and low 
encapsulation efficiency reported (Ratajska and Boryniec, 1998; Rao and Geckeler, 
2011). On the other hand synthetic polymers have the advantage of sustaining the 
release of the incorporated active agent over a period of days to several weeks and 
they offer better reproducibility of the synthesized NPs as compared to natural 
polymers (Rao and Geckeler, 2011). Moreover natural polymers are in general 
inadequate by the use of organic solvents and relatively harsher formulation 
conditions. 
Synthetic polyesters are among the most used in the drug delivery application, as 
encapsulation agents, controlled drug release and site specific delivery. These 
include polylactic acid (PLA), poly-glycolic acid (PGA), poly (D,L lactide-co-
glycolide) (PLGA), PCL etc (Soppimath et al., 2001 ). The advantage of using these 
polymers is that they are biocompatible, biodegradable and US-FDA-approved 
materials.  
PCL has found various biomedical applications such as in drug delivery, suture and 
scaffold in tissue engineering (Woodruff and Hutmacher, 2010). PCL is hydrophobic 
polyester. It undergoes hydrolysis upon implantation into the body, forming 6-
hydroxylcaproic acid that is converted into acetyl-CoA and enters the normal citric 
acid cycle. The products are eventually eliminated from the body without causing 
any harm as shown in Fig.1.5 (Woodruff and Hutmacher, 2010). Furthermore it is 
cheaper and degrades slower when compared to other polyesters. For these 
reasons, PCL was selected as a polymer of choice in the present project. 
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Figure 1.5: Hydrolysis of polycaprolactone polymer (Woodruff and Hutmacher, 
2010) 
1.5.5 Significance of the study 
The proposed study is relevant since literature search available on the FDA-
approved PCL polymeric NPs loaded with ARV’s is limited, particularly that deals 
with the nano-encapsulation of LAM and EFV. Furthermore most work involving 
nano-encapsulation of LAM and EFV into polymeric materials is mainly based on 
the use of the freeze drying technique which is not scalable. The aim is to use 
scalable spray drying technique and, we therefore hypothesize that when using this 
system to prepare NPs; drug release can be prolonged, allowing for a single 
administration of drugs to last for several days or weeks instead of the current daily 
administration 
1.6 Outline of the dissertation 
The work presented in this study is outlined in the following five chapters. 
Chapter 1 introduces the problems associated with the current ARVs used in the 
treatment of HIV/AIDS and emphasizes on the need to nano-encapsulate the two 
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existing drugs namely LAM and EFV into PCL polymer.LAM and EFV are from two 
different classes of ARVs. LAM is hydrophilic and EFV is hydrophobic, as results 
double emulsion spray drying method is proposed to nano-encapsulate the drugs. A 
concise general introduction is provided while highlighting the aims, objectives and 
justification of the proposed research project. 
Chapter 2 contains the literature review of the HIV/AIDS disease, what has been 
done to reduce the viral load or attempted to cure the virus with the ARVs. 
Nanoencapsulation or inclusions of the exciting ARVs (LAM and EFV) within the 
approved materials are described in detail. 
Chapter 3 describes the preparation of PCL-LAM NPs, an anti-HIV hydrophilic 
drug. A method used to produce the novel PCL-LAM nanoparticles is shown. Prior 
the optimizations of an effective method, different solvents, a mixture of the 
solvents, drying excipients were assessed. Characterizations of the prepared PCL-
LAM NPs using different techniques are presented. Finally the in vitro drug release 
of LAM from the PCL NPs is evaluated.  
Chapter 4 establishes the nano-encapsulation of the hydrophobic drug, EFV into 
PCL polymer and subsequent method development used in producing novel PCL-
EFV NP’s is provided. The obtained results on the use of different solvents, drying 
excipients are presented. The optimized formulation based on the obtained results 
was implemented to produce PCL-EFV nanoparticles. The assessments of the 
PCL-EFV nanoparticles using different characterization techniques are shown and 
in vitro release of EFV is included. 
Chapter 5 gives the conclusions and recommendations of the research work 
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CHAPTER 2:  
 BACKGROUND AND SIGNIFICANCE 
 
 
2.1 Overview of HIV/AIDS disease 
AIDS is a leading deadly infectious disease in adults particularly in the sub-Saharan 
Africa as shown in Table 2.1 (Hauck et al., 2010, UNAIDS, 2011), and worldwide it 
has claimed over 25 million lives since its discovery in 1981 (Sharma and Garg, 
2010). The first death caused by AIDS was traced in 1959 in a blood specimen 
obtained at Kinshasa the capital city of Congo (Gupta and Jain, 2010). The 
causative agent was for the first time identified by Luc Montagnier and co-workers 
in 1983 as HIV (Gallo and Montagnier, 1987). The identification of AIDS is given to 
HIV infected patients when their cluster designation (CD) 4 positive (+) T-cell count 
falls below 200 cells per cubic millimeter (mm3) (National Institute of Allergy and 
Infectious Diseases (NIAID), 2011), compared to 600 to 1000 cells per mm3 for a 
healthy person. 
HIV falls into retroviridae family and is classified as a lentivirus (Levy, 2007). 
Lentiviruses often cause immunodeficiency in their host by killing the CD4+ T-cell 
(Gupta and Jain, 2010). By doing so it allows life threatening opportunistic 
infectious diseases like TB to succeed (Rao et al., 2009 ). There are two major 
classes of HIV namely, HIV-1 and HIV-2 that can cause AIDS (Thomson and 
Nájera, 2005, Neves et al., 2010). HIV-1 is mostly found in central Africa, North 
America, Europe, Asia, Australia, while HIV-2 is prevalent in West Africa (Thomson 
et al., 2002, Neves et al., 2010). These two viruses are closely related; differ in their 
biological origin and in some accessory genes. However HIV-2 is less dangerous 
than HIV-1 and known by its slower progression to AIDS (Silva et al., 2008).  
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Table 2.1: A global view of adults living with HIV (UNAIDS, 2011) 
 People living with HIV 
2010 
New HIV infections AIDS-related deaths 
2010 
Adult HIV prevalence 
(%) 
sub-Saharan Africa 22.9 million 
[21.6 –24.1 million] 
1.9 million 
[1.7 –2.1 million] 
1.2 million 
[1.1–1.4 million] 
5% 
[4.7%–5.2%] 
 
Middle East and North 
Africa 
 
470 000 
[350 000–570 000] 
59 000 
[40 000–73 000] 
35 000 
[25 000–42 000] 
0.2% 
[0.2%–0.3%] 
 
South and South-East 
Asia 
4.0 million 
[3.6–4.5 million] 
270 000 
[230 000–340 000] 
250 000   
[210 000–280 000] 
0.3% 
[0.3%–0.3%] 
 
East Asia   790 000 
[580 000–1.1 million] 
88 000 
[48 000–160 000] 
56 000 
[40 000–76 000] 
0.1% 
[0.1%–0.1%] 
Oceania 54 000 
[48 000–62 000] 
3300 
[2400–4200] 
1600 
[1200–2000] 
0.3% 
[0.2%–0.3%] 
Latin America 1.5 million 
[1.2–1.7 million]   
100 000 
[73 000–140 000] 
67 000 
[45 000–95 000] 
0.4% 
[0.3%–0.5%] 
 
Caribbean 200 000 12 000 9000 0.9% 
 21 
[170 000–220 000] [9400–17 000] [6900–12 000] [0.8%–1.0%] 
 
Eastern Europe and 
Central Asia 
 
1.5 million 
[1.3–1.7 million]   
160 000 
[110 000–200 000] 
90 000 
[74 000–110 000]   
0.9% 
[0.8%–1.1%] 
 
 
Western and Central 
Europe 
 
840 000 
[770 000–930 000] 
30 000 
[22 000–39 000] 
9900 
[8900–11 000]   
0.2% 
[0.2%–0.2%] 
 
North America 1.3 million 
[1.0–1.9 million] 
58 000 
[24 000–130 000] 
20 000 
[16 000–27 000] 
0.6% 
[0.5%–0.9%] 
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HIV can be seen as a biological nanostructure that has a diameter of around 100 to 
150 nm, spherically in shape as shown in Fig. 2.1 (Neves et al., 2010). It is 
composed of nucleocapsid and genetic material in the form of ribonucleic acid (RNA) 
containing three structural genes, taken from the membrane of the human cell when 
the newly formed virus particle buds from the cell (NIAID, 2009). Infection with HIV 
occurs by sexual contacts with infected partner, needles and from mother to child in 
infected individual during pregnancy or breast feeding (Gupta and Jain, 2010). Once 
inside the human body, the virus can go through the human cell in three important 
mechanisms (see Fig. 2.1) (Rao et al., 2009 ) 
 Binding of the HIV surface glycoprotein (gp) 120 to the CD4 receptor situated on 
the cell membrane. These receptors are expressed by the monocyte derived 
macrophages and T-lymphocytes 
 Interaction of the gp 120 protein and CD4 complex with a co- receptor 
 Virus-cell membrane mediated by trans-membrane gp 41 protein 
 Figure 2.1: HIV replication cycle and targets for antiretroviral therapy. 
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After binding with the human cell, two viral enzymes namely reverse transcriptase 
(RT) and integrase are released into the cytosol of the host cell. The RT enzyme 
then transcribe the single stranded RNA into double stranded deoxyribonucleic acid 
(DNA), followed by integration of the viral DNA into the host genome resulting in the 
formation of a provirus (Rao et al., 2009 ) 
2.2 Current status of HIV treatment 
The identification of HIV as the primary cause of AIDS, has launched an intensive 
research campaign to find active agents that can target various steps in the  HIV 
replication cycle (Clercq, 2009). The first active agent to be used as an anti-HIV 
drug, zidovudine, received the US-FDA approved in 1987, demonstrating a 
significant clinical proof-of-concept that HIV virus might be treated with 
chemotherapy (Este' and Cihlar, 2010). Today there are more than 25 anti-HIV drugs 
known as the ARVs therapy some of which are also available in a FDC. These drugs 
fall into six mechanistic classes as shown in Fig. 2.1 and  categorized as (Este' and 
Cihlar, 2010): 
 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/nRTIs)  
 non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
 protease inhibitors (PIs)  
 integrase inhibitors 
 entry/fusion inhibitors (FIs) 
 chemokine receptor antagonists (CRAs) 
NRTIs/nRTIs are the first class of ARVs that were approved for the treatment of HIV 
infection. They show potent activity against both HIV-1 and HIV-2. Most 
NRTIs/nRTIs require phosphorylation by intracellular activation to become NRTIs-
triphosphates. Once activated, these active agents compete with the RT enzyme; an 
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enzyme that HIV virus needs to transcribe the single stranded RNA into double 
strand DNA. Collectively, the oral bioavailability of NRTIs ranges from 25% to 93%, 
and the approved drugs include zidovudine, didanosine, zalcitabine stavudine, LAM , 
abacavir, and emtricitabine.Tenofovir is the only US-FDA approved NRTIs/nRTIs, 
that skips the activation stage. Since is already monophosphorylated (Rathbun and 
Greenfield, 2011, Sosnik et al., 2009). 
NNRTI also targets the RT enzyme, but unlike NRTIs, these drugs do not require 
intracellular activation. They show potent activity against HIV-1 and they were first 
introduced in 1998, which includes EFV, nevirapine, delavirdine. In addition to these 
drugs etravirine and rilpivirine were recently FDA approved. Etravirine show activity 
against HIV-2 in addition. NNRTIs shows a serum half-lives ranging from 25-55 
hours, except for delavirdine, which has a shorter half-life of 2-11 hours (Rathbun 
and Greenfield, 2011, Gupta and Jain, 2010, Sosnik et al., 2009). 
PIs are pro-drugs that compete with HIV protease, by directly binding to HIV 
protease and prevent subsequent cleavage of polypeptide. HIV protease is a 99-
amino-acid, aspartic acid protein and is responsible for maturation of virus particle 
late in the HIV replication cycle. They were first introduced in 1995 and a total of 8 
compounds namely saquinavir, indinavir, lopinavir, nelfinavir, fosamprenavir, 
atazanavir, tipranavir and darunavir. They have relatively short serum half-life, 
ranging from 1.5 to 2 hours for indinavir, 7 hours for atazanavir, and exhibit activity 
against both HIV-1 and HIV-2 (Rathbun and Greenfield, 2011, Gupta and Jain, 
2010). 
Integrase enzyme of HIV particle was for the first time elucidated in 1994, thus 
opening the new possibilities to address the infection with ARVs that can interact and 
inhibit with the enzyme. HIV integrase enzymes are responsible for the 
transportation and attachment of provirus DNA to the human cell genome, allowing 
the transcription of the viral proteins and subsequent assembly of new virus 
particles. The integrase inhibitors therefore inhibit the enzyme integrase and prevent 
the integration of the viral DNA into the host cell. The first drug to be approved by 
FDA was raltegravir, and another promising drug, elvitegravir is still in the phase 3 
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clinical trials. Raltegravir has the a half life of 10 to 12 hours, and it can be taken with 
or without food (Rathbun and Greenfield, 2011). 
FIs also known as entry inhibitors are a class of drugs that prevent HIV particle from 
the CD4+ cells or any targeted cells. They received US-FDA approval in 2003, and 
currently the only marketed drug from this class is enfuvirtide. Enfuvirtide prevents 
the second step in the fusion pathways by attaching to the heptad-repeat (HR) 1 of 
the gp 41. Chemokine receptor, antagonists are another class of ARVs, that has the 
mechanism of action as FIs. They normally block the HIV entry into the healthy 
CD4+ cells. Maraviroc is the only current drug from this class, which received the 
FDA approval in August 2007. It has a half life of 15-30 hours (Rathbun and 
Greenfield, 2011). 
The different classes of ARVs described above are the most important for effective 
management of HIV. The two objectives of the ARV therapy are, to stop the 
progression of HIV to AIDS by maintaining suppression of the viral replication and 
restoration of the immunity by restoration of CD4+ cells (Gupta and Jain, 2010). In 
order to achieve these objectives, a standard treatment known as HAART as 
previously mentioned is required. HAART consists of three or more ARVs from 
different classes (Sharma and Garg, 2010; Sosnik et al., 2009, Clercq, 2009), with 
the purpose to target different steps in the viral replication cycle simultaneously. 
Since the mid 1990s, these combinational therapies have brought significance 
improvements by changing the well being of the HIV infected patient. Today HAART 
is considered as the main advances in the field of HIV/AIDS therapy (Sharma and 
Garg, 2010;). As the results, HIV/AIDS infected patient’s lives may be increased from 
less than 1 year to more than 10 years (Shahiwala and Amiji, 2007) 
2.3 Limitations of the current HIV treatment 
The current ARVs are effective in chronically suppressing the virus replication and 
limiting the progression of the HIV to AIDS, however the strategic plan to cure the 
virus has been unsuccessful (Kim and Read, 2010). The challenge facing current 
HIV treatment include (Este' and Cihlar, 2010; Neves et al., 2010): 
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 high doses taken daily 
 adverse effects 
 poor patient adherence 
 drug resistance 
 chronic disease 
Most ARVs are administered orally and some undergo extensive gastrointestinal (GI) 
degradation and first pass metabolism, which results in low bioavailability (Sosnik et 
al., 2009). To overcome the factor of drug resistance US-FDA-approved drugs, e.g. 
etravirine, which are to be used in patience that resistance has developed with other 
ARVs. However due to their recent approval, their practicalities and technological 
problems are unknown. Thus over the coming year’s clinical experience will probably 
show their biopharmaceutical weaknesses and disadvantages (Sosnik et al., 2009). 
More importantly, HIV primarily resides in the anatomical (i.e. the central nervous 
system, lymphatic system, liver etc) and cellular reservoirs (i.e. CD4+ T lymphocytes 
and macrophages/monocytes) of the human body, which is the main problem as the 
ARVs cannot reach these places in therapeutic concentrations (Gupta and Jain, 
2010; Rao et al., 2009). Thus there is an urgent need for new novel DDS that will be 
able to improve challenges facing HIV treatment. In this context nanomedicine has 
emerged as a promising technology. The current methods of nano-encapsulating 
drugs, controlled release can be achieved over days to months, thus decreasing high 
dosage intake, minimizing adverse side effects, and consequently increasing 
patience adherence. 
2.4 Application of nanomedicine in HIV treatment 
Nanomedicine is defined as the use of materials roughly around 1 to 1000 nm (Kim 
and Read, 2010; Mamo et al., 2010). This is due to the fact that these structures 
present distinctive physicochemical properties due to their small size, surface area, 
chemical composition, surface structure, solubility and shape (Semete et al., 2010). 
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These properties have been found to yield advantages across various fields of 
medicine including drug or gene delivery, imaging and diagnostics. The overall goal 
of nanomedicine is exactly the same as that of medicine: to diagnose as accurately 
early as possible and to treat as effectively as possible without any detrimental 
effects (Mishra et al., 2010). The field of drug development and delivery has been 
faced with a variety of challenges such as the following (Muller and Keck, 2004): 
 Poor drug solubility 
 Low bioavailability 
 Low in vivo stability 
 Adverse side effects 
Recently the use of NPs has attracted a great deal of interest in the field of HIV/AIDS 
treatments. Different types of NPs have been shown by various researchers to 
address the aforementioned major problems in many drugs (Sharma and Garg, 
2010). The following section covers the cutting research edge of nanotechnology 
developed over the past years for the treatment of HIV/AIDS. Emphasize is based on 
the polymer based technology particularly polymeric nanoparticles aimed at 
improving the current treatment, as these systems are more stable when compared 
to other systems. Other delivery methods such as polymeric micelles, cyclodextrins 
and dendrimers are also discussed as they have the potential to improve the current 
treatment of HIV/AIDS. 
2.5 NPs as drug delivery systems 
The first commercially available NPs drug delivery system, ABRAXANE ®, for breast 
cancer application was approved by US-FDA in January 2005. This drug delivery 
system is based on albumin-bound (nab ®) paclitaxel, showed better and faster rate 
of shrinking tumors in 460 patients with metastic breast cancer, almost double 
compared with solvent-based taxol ® (Astete, 2005). Today more than five systems 
are US-FDA approved, mainly for cancer treatment (Kingsley et al., 2006). These  
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Tablets
Micropaticles
Nanoparticles
NPs systems have been successfully employed mainly in cancer treatment as shown 
in Table 2.2, therefore we now have better understanding of the practicalities and 
technicalities linked with their clinical improvement to develop other  NPs based on 
the HIV/AIDS treatment (Sharma and Garg, 2010). The basic requirements for their 
clinical developments, is that the material used to prepare them must be 
biodegradable, biocompatible and non-toxic. The most important factors that attracts 
many researchers to develop these NPs is that the particle size is sub-micron, 
surface charge can be modified, the up-take is sufficient compared to large particles, 
and more importantly controlled release is prolonged as compared to other 
formulations (Fig. 2.2) (Kumar et al., 2002), thus facilitating higher bioavailability. 
 
 
Figure 2.2: Drug release efficiency of various formulations (Kumar et al., 2002). 
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2.5.1 Significance of particle size and surface charge in nanomedicine 
The NPs offer many distinctive rewards over microparticles. The sub-micron sized 
enables higher intracellular up-take when compared to microparticles. This was 
demonstrated whereby 100 nm size NPs showed 2.5 fold greater up-take compared 
to 1 μm and 6 fold higher up-takes when compared to 10 μm particles in Caco-2 cell 
line (Desai et al., 1997). Other researchers have shown that the sub-micron particles 
can cross the blood-brain-barrier (BBB) of the central nervous system (CNS), which 
is one place where current ARVs cannot reach appropriately (Rao et al., 2009). Such 
strategy could provide sustained delivery of ARVs across the brain. 
Surface charge of the NPs is one of the factors that tend to affect the up-take and 
targeting of the drug loaded NPs. It has been shown that the probabilities of the NPs 
to escape the endo-lysosomes mode of uptake depends on the surface charge. NPs 
that show transition in their surface charge from anionic (pH 7) to cationic in the 
acidic endosomal pH ( pH 4-5) are found to escape the endosomal compartment 
whereas the  NPs which remain negatively charged at pH 4, were retained mostly in 
the endosomal compartment. Moreover NPs coated with the hydrophilic moieties 
tends to minimize they clearance in the body, thus increasing their circulation (Muller 
and Keck, 2004). Lately, it was demonstrated that positively charged NPs coated 
with natural polymers like chitosan were able to open the tight junction (Dev et al., 
2010). 
 
 
 
 
 
 
 30 
Table 2.2: US-FDA approved NPs DDS (Bharali and Mousa, 2010) 
Product Company Drug Formulation ROA Application Status 
Abraxane 
DaunoXome ™ 
 
Emend® 
Caelyx® 
 
 
Abraxis Bioscience, 
AstraZeneca 
NeXstar Pharmaceutica 
 
Merck/Elan 
Schering-Plough 
Paclitaxel 
Daunorubicin 
citrate 
Aprepitant, 
MK869 
Doxorubicin 
Albumin-bound 
nanoparticles 
Liposome 
Nanocrystal particles 
Pegylated liposome 
Iv 
Iv 
Oral 
im 
Metastatic breast cancer 
Kaposi sarcoma in AIDS 
patients 
Chemotherapy-related 
nausea and vomiting 
Metastatic breast and 
ovarian cancer;Kaposi 
sarcoma 
In market 
In market 
In market 
In market 
Myocet® 
Doxil ™ 
DaunoXome ™ 
L-Annamycin 
Zeneus Pharma Ltd 
Sequus Pharmaceutical 
NeXstar Pharmaceutica 
Callisto Pharmaceuticals 
Doxorubicin 
Doxorubicin 
Daunorubicin 
citrate 
Annamycin 
Liposome 
Liposome 
Liposome 
Liposome 
Iv 
Iv 
Iv 
iv 
Metastatic breast cancer 
Kaposi sarcoma 
Kaposi sarcoma 
Children and young 
adults with refractory or 
relapsed ALL or AML 
In market 
In market 
In market 
Phase I/II 
SLIT™Amikacin 
N/A 
Transave, Inc. 
North Central Cancer 
Treatment Group   
Cisplatin 
Paclitaxel, 
carboplatin, 
temozolomide, 
bevacizumab 
Liposome 
Albumin nanoparticles 
Aeros
ol 
iv 
Lung cancer; pulmonary 
metastases 
Stage IV malignant 
melanoma that is 
efractory to surgical 
removal 
Phase II 
Phase II 
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Genexol-PM 
CALAA-01 
Samyang Pharmaceuticals 
Calando Pharmaceuticals 
Paclitaxel 
Anti-R2 siRNA 
Methoxy PEG–PLA 
Cyclodextrin-containing 
polymer(CAL101) and 
targeting agent (AD-
PEG-Tf) 
Iv 
iv 
Breast and lung cancer 
Solid tumors that are 
refractory to standard-of-
care 
Phase II 
Phase I 
Rexin-G 
 
BikDD 
Nanoparticle 
 
Docetaxel-PNP 
NL CPT-11 
Epeius Biotechnologies 
 
  M.D. Anderson Cancer 
Center/NCI 
Samyang 
University of California, San 
Francisco 
Dominant 
negative cyclin 
G1 construct 
Pro-apoptotic 
Bik gene 
(BikDD) 
Docetaxel 
CPT-11 
Pathotropic 
nanoparticles 
 
Liposome 
 
Polymeric nanoparticles 
Liposome 
Iv 
 
Iv 
 
Iv 
iv 
Recurrent or metastatic 
breast cancer 
 
Pancreatic cancer 
 
Advanced solid 
malignancies 
Recurrent high-grade 
gliomas 
Phase I/II 
 
Phase I 
 
Phase I 
Phase I 
ROA,  route  of  administration;  iv,  intravenous;  im,  intramuscular;  ALL,  acute  lymphocytic  leukemia;  AML,  acute  
myelogenous  leukemia;  PEG–PLA,  poly(ethylene  glycol)–poly(lactide);  Tf,  human  transferrin  protein;  PBCA-
NPs,polybutylcyanacrylate nanoparticles; HCC, hepatocellular carcinoma; DMPC, dimyritoylphosphatidylcholine; DLPC, 
dilauroylphosphatidylcholine
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2.6 Polymer based NPs 
2.6.1  Polymeric NPs 
Polymeric NPs (PNPs) are materials that generally have size that range from 10 to 
1000 nm (Reis et al., 2006). Biodegradable and non-biodegradable particles can 
be developed, but for the aim of investigating the use of these polymers in drug 
delivery applications, biodegradable polymers are of great importance. PNPs is a 
collective name for nanocapsules and nanospheres as shown in Fig. 2.3. 
Nanocapsules are vesicular systems in which drug molecules are surrounded by a 
polymeric membrane and nanospheres are a matrix system in which drug 
molecules are encapsulated or dispersed throughout the polymeric particle 
(Mishra et al., 2010). The simplicity and versatility of nanotechnology allows these 
systems to be prepared using various methods, see Fig. 
2.4.
 
Figure 2.3: Representation of nanosphere and nanocapsule (Mishra et al., 2010). 
There is a wide spectrum of natural, semi-synthetic and synthetic polymers that 
have been proposed as therapeutic platforms. For effective use for treatment in 
the field of nanomedicine, it is important to know the true value of a given polymer, 
understand its precise physico-chemical characteristics and purity of the 
compounds used in biological studies (Duncan, 2011). The key features that 
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govern suitability of the polymer to be employed or developed for therapeutics are 
shown in Table 2.3. 
 
Figure 2.4: Formulation of nanocapsules and nanospheres using various nano-
formulations (Kumari et al., 2010) 
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Table 2.3: Issues relating to the suitability of polymers and / or their conjugates for 
development as nanomedicines (Duncan, 2011) 
Key issues for consideration include: 
i. Potential toxicity following acute or chronic use ( i.e. safety) – this relates to 
the route of administration, dose needed and frequent/duration of 
administration, 
ii. The likely primary metabolites and their fate following acute or chronic 
administration, 
iii. Ability to manufacture reproducibility and/or to achieve a 
minimal/acceptable degree heterogeneity in polymer composition in respect 
of safety/efficacy- all polymers will display some degree of heterogeneity in 
terms of molecular weight, and also when the polymer is non-linear (i.e. 
branched, dendritic, etc.) or composed of more than one monomer other 
forms of heterogeneity can be present, 
iv. For multifunctional structures, is it possible to achieve validated 
characterization of all components in the presence of the others? 
v. Ability to produce a pharmaceutical formulation with acceptable stability 
(shelf-life) and suitability for patient administration 
vi. Ability to display the cellular and whole body pharmacokinetics needed to 
ensure access to the pharmacological and thus reproducibly efficacy 
(includes need for stability in transit and /or appropriate drug release rate at 
pharmacological target). 
vii. Will the construct be cost-effective to produce as a medicine? 
viii. Terminology- to note often polymers are mentioned by name  e.g. 
Polyethylene glycol (PEG) without additional information of molecular 
weight, polydispersity, architecture, etc, Such variations have a profound 
effect on pharmacokinetics and thus impact on the safety and efficacy of the 
conjugate, that is not all PEGylated conjugates contain the same PEG!! 
 
Addressing issues relating to safety of the PNPs, is one of the strategic plans to 
facilitate their US-FDA approval, as these materials are to be used in living 
organisms. Semete and co-workers (Semete et al., 2010) synthesized NPs of 
PLGA using spray-drying and freeze-drying double emulsion methods. They 
evaluated the effect of these NPs in vitro and in vivo compared to the industrial 
NPs made from metallic compounds of similar size range. These NPs included 
ferrous oxide, zinc oxide and fumed silica. Findings showed that an in vitro 
cytotoxicity study performed at concentrations of 0.1, 0.01 and 0.001 mg/ml on the 
CaCO-2 cell and HeLa cells using water soluble tetrazolium (WST) assay, 
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presented viability of more than 75%. They found that these results were similar 
when compared to those with the amorphous fumed silica particles and ferrous 
oxide, but the cell viability was reduced for zinc oxide NPs. The in vivo toxicity 
study was done by oral administration of the PLGA NPs in Balb/C mice using 
histopathological evaluation assay. Findings presented no specific anatomical 
pathological changes or tissue damage. However the mice administered with the 
zinc oxide NPs died or lost weight, showing the toxicity of the NPs. 
It has been known over decades that macrophages are responsible for the 
dissemination of the HIV virus in the body (Dutta and Jain, 2007). Using the 
current treatment it is not possible to deliver the ARVs in the anatomical reservoirs 
and the CNS as explained early. Following the efforts to conquer these obstacles, 
(Shah and Amiji, 2006) prepared the poly(ethylene oxide)-modified-poly(epsilon-
caprolactone) (PEO-PCL) NPs by a solvent displacement method. The aim of the 
study was to increase the intracellular of saquinavir, which has an oral 
biovailability of only 4%. The size of the prepared saquinavir loaded PEO-PCL 
loaded NPs were in the range of 267.7 to 275.3 nm. The drug release showed an 
initial burst, within the first hour of the study in phosphate buffered saline (PBS) 
containing Tween 80 at 37oC. The cellular uptake of the NPs coated with 
rhodamine-123, showed that the NPs were taken by the cells of 
monocyte/microphages.  
The release of the drug nano-encapsulated into PNPs is an important factor as 
many “naked” ARV drugs tend to degrade in the stomach conditions, subsequently 
a reduced bioavailability is observed (Sosnik et al., 2009). Dev and co-workers 
(Dev et al., 2010) synthesized poly(lactic acid)/chitosan (PLA/CS) NPs using 
freeze-dried double emulsion method using LAM as a drug model. Two batches of 
the NPs were prepared, the first contained the 3% drug loading and the second 
6% drug loading. The in vitro studies showed that the drug release rate was much 
lower in the acidic pH media when compared to higher release rate in the alkaline 
pH media, as given in Fig 2.5. The authors concluded that this behavior was due 
to the positive charge present in the NPs due to chitosan and the H+ ions present 
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in the acidic pH. In addition the cytotoxicity study was also performed using the 
MTT assay, and findings showed that no cell died when NPs were introduced.  
 
Figure 2.5: Drug release rate of 3% (I) and 6% (II) drug loaded NPs.  
ARVs are usually used in a combination to suppress the viral load in an HIV 
infected patient. Destache et al prepared the PLGA nanoparticles using w/o/w 
homogenization (Destache et al., 2009). The prepared NPs were loaded with three 
anti-HIV drugs namely ritonavir (RTV), lopinavir (LPV) and EFV. The drug loading 
and encapsulation efficiency were 4.9, 5.2, 1.9% and 38%, 45% and 86% for RTV, 
LPV and EFV respectively. The in vitro drug release from the PLGA nanoparticles 
incubated with polymophonuclear (PBMCs) cells was also conducted. Findings 
showed that the intracellular concentrations peaked at 96 hours (RTV 2.5±1.1, 
LPV 4.1± 2.0 μg), and EFV peaked at 24 hours (12.6±2.7 μg). All three drugs 
continued to be released for 28 days. When these results were compared with free 
drug incubated with the PBMCs, intracellular concentration of the 3 drugs peaked 
at 8 hours (RTV 5.1±0.05, LPV 4.3±.03, and 3.1±0.02 μg). However the drugs 
were eliminated within 2 days. 
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2.6.2 Polymeric micelles 
Polymeric micelles are formed from block copolymers that have amphiphilic 
character. Amphiphilic polymers are copolymers composed of hydrophilic (“water 
loving”) and hydrophobic (“water hating”) parts (Wilson, 2001). They normally form 
spontaneously under certain concentrations and temperatures in a given media 
(Torchilin, 2006). The concentration at which these micelles are formed is known 
as critical micelle concentration (CMC), while the temperature at which this micelle 
exist is called the critical micellization temperature (CMT) (Torchilin, 2006). 
Hydrophobic blocks of amphiphilic polymers form the core of the micelle, while the 
hydrophilic blocks form the shell (Kataoka et al., 2001; Attwood and Florence, 
1983). They can be utilized as drug carriers, by incorporating the poorly soluble 
nonpolar substances within the micellar core, polar substances on the micellar 
shell (by adsorption), substances with intermediate polarity are distributed 
between core and shell (Torchilin, 2006, Adams et al., 2003). These properties 
enable these systems to incorporate poorly-water soluble drugs in the micellar 
core by physical interaction or by chemical conjugation leading to higher solubility 
extents (Sosnik et al., 2010), to protect the drugs or sensitive substances from 
premature degradation and also reduce the toxicity of the drug (Kataoka et al., 
2001 ). When compared to conversional micelles, polymeric micelles have lower 
CMCs values, and are more stable even at concentrations below CMC (Torchilin, 
2006). This behavior stems from the slower rate of dissociation that depends on 
the molecular weight and hydrophilic-hydrophobic balance of the polymer as well 
as the properties of the drug incorporated into the core (Sosnik et al., 2010).  
Increasing oral bioavailability of EFV and make the drug suitable for children and 
people experiencing difficulties in swallowing the solid form of the drug, Chiappetta 
et al (Chiappetta et al., 2010) loaded EFV into polymeric micelles of Pluronic® F 
127, a poly(ethylene oxide)-poly(propylene oxide) linear block copolymer. The 
pharmacokinetics of the prepared formulation was compared to that of a 
suspension with the content of EFV capsules in 1.5% carboxymethlcellulose PBS 
solution, and an EFV solution prepared in medium-chain triglyceride. The 
bioavailabilities of the prepared formulations were assessed in a male Wistar rats. 
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Findings showed that EFV-loaded micelles led to higher plasma concentrations 
and plasma areas-under–the-curve that were greater than that of EFV prepared in 
a buffer and one in medium-chain triglyceride. The group further investigated the 
stability and organoleptic associated with the drug (Chiappetta et al., 2010), since 
EFV tends to imparts burning sensation in the mouth. Findings showed that EFV-
loaded micelles are more physicochemically stable when compared to other 
systems, and that they improve the taste associated with the drug as the prepared 
formulation could include sweeteners in order to enhance or increase compliance 
in children 
2.6.3 Cyclodextrins 
Cyclodextrins are cyclic (α-1, 4)-linked oligosaccharides of α–D glucopyranose 
units derived from starch. These types of oligosaccharides normally have the 
hydrophobic cavity and the hydrophilic outer surface. Currently the marked class 
of cyclodextrins include, α-cyclodextrins, β-cyclodextrins and γ-cyclodextrins 
containing 6, 7 and 8 (α-1, 4)- linked α–D glucopyranose units, also their 
derivatives are in use. Their main use in the pharmaceutical standpoint, are the 
ability to form complexes with drugs, able to improve the aqueous solubility of 
biopharmaceutical classification system (BCS) class 2 or 4 materials, ability to 
increase the bioavailability, and stability of many drugs (Brewster and Loftsson, 
2007). 
Sathigari and co-workers (Sathigari et al., 2009 ) studied the inclusion complexes 
of EFV into β–cyclodextrin, including their derivatives, namely hydroxypropyl-β-
cyclodextrins (HP βCD), and randomly methylated-β-cyclodextrins (RM βCD) in 
order to improve the solubility of the drug. Outcomes showed that the group was 
able to complex EFV into cyclodextrins. Among the different studied systems HP 
βCD and RM βCD exhibited the amorphous pattern of the compound when XRD 
was used. These results were further supported by DSC, indicating the absence of 
the melting enthalpy of the drug. The overall results showed that amorphous form 
of EFV was prepared and it was possible to incorporate EFV into cyclodextrins. 
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More recently (Shown et al., 2010) the lactose based oligomers of β-cyclodextrins 
were prepared by using condensation polymerization process to improve the 
solubility of EFV. Findings showed that the characterictics peak of EFV was 
absent when FTIR was used, suggesting that EFV was nano-encapsulated in the 
core of the chain. Using of XRD and TGA, the prepared compound was 
amorphous and relatively more stable when compared to the free drug. 
Cytotoxicity studies indicated that the toxicity of the drug was also reduced 
2.6.4 Dendrimeric polymers 
Dendrimers are another type of monodisperses macromolecules that are highly 
branched. The word is derived from the Greek, “dendron” meaning a tree, as 
shown in Fig. 2.6. This branching structure that emerges from the center can be 
prepared either by divergent or convergent synthetic methods. Their unique 
architecture allows dendrimers exhibit significantly improved physico-chemical, 
properties when compared to linear polymers. The presence of different chain-
ends which are capable to impart high solubility, miscibility, and high reactivity, as 
results they have gained ground to be utilized in areas of nanomedicine. For drug 
delivery applications, the drug can be loaded both in the interior as well as 
conjugated to the surface groups (end groups) of the dendrimer. More importantly 
these structures can be created to match a certain biological activity, or as a 
targeting material, since these molecules are small enough to pass through the 
cells (Holister et al., 2003, Klajnert and Bryazewska, 2001). 
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Figure 2.6: Schematic representation of the fourth generation dendrimer (Klajnert 
and Bryazewska, 2001). 
Dutta and Jain synthesized fifth generation dendrimer based of 
poly(propyleneimine) (PPI) polymer, and one coated with mannose, namely 
mannosylated poly (propyleneimine) (MPPI) by using the divergent method. The 
prepared PPI and MPPI-dendrimers were loaded with LAM. These dendrimer 
nanoparticles were made to target MT-2 cells and to increase the cellular uptake 
of the drug. The results showed that the entrapment efficiency of the LAM drug 
was higher in the MPPI than PPI with 43.27±0.13% and 35.69±0.20% respectively. 
The effect was also observed in the in vitro analyses that MPPI was able to 
release the drug for 144 hours as opposed to PPI which showed the released only 
until 24 hours. MT2 cells showed that, there was a significant enhancement in the 
cellular uptake of the drug when MPPI was used, which was 21 times higher than 
the free drug at 48 hours. PPI cellular uptake was 2.5 times higher than the free 
drug. The authors attributed these results to the interaction of MPPI with the lectin 
receptors that are found on the surface of the MT2 cells, while with PPI was due to 
cationic properties thus leading to efficiently interact with negatively charged 
membranes (Dutta and Jain, 2007). 
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CHAPTER 3:  
NANO-ENCAPSULATION OF WATER SOLUBLE DRUG, 
LAMIVUDINE USING A DOUBLE EMULSION SPRAY DRYING 
TECHNIQUE FOR IMPROVING HIV TREATMENT 
 
 
3.1 Introduction 
DDS using the field of nanotechnology, has reached the long-term goal of medicine, 
to diagnose as accurately, treat as early as possible efficiently without causing any 
harm (Mishra et al., 2010). In order to reach these goals, polymers have gained 
ground over the years, because of their biodegradable and biocompatible properties. 
The nano-encapsulation of therapeutic agents into PNPs is one of the important 
ideas in the field of DDS, since therapeutic agents can be protected from external 
environment to hinder premature degradation before reaching side of target (Jyothi 
et al., 2010; Kumari et al., 2010). To a more complex form, these polymers can be 
attached with special ligand(s) to deliver the therapeutic agents to particular 
compartments in the body, thus increasing the efficacy of the drug (Rao et al., 2009). 
The notion of protecting and targeting drugs stems from the very idea of minimizing 
the risk-to-benefit ratio (Mishra et al., 2010). 
LAM, an anti-HIV drug that falls under NRTIs, has shown activity against RT 
enzyme. It is a hydrophilic drug with half life of 5 to 7 hours, and classified as Class 1 
in the BCS, denoting that it has high solubility and permeability (Jozwiakowski et al., 
1996). The daily suggested dose of 150 mg is required for life time (Kao et al., 2000). 
The oral administration of LAM exhibits side effects such as abdominal pain, 
headache, nausea, fatigue and also vomiting (Caroline and Faulds, 1997). 
Recently Dev and co-workers nano-encapsulated LAM into polylactide/chitosan 
(PLA/CS) NPs using the double emulsion freeze-drying method (Dev et al., 2010). 
Findings showed that it was possible to synthesize the NPs, without changing the 
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structural integrity of the two polymers and a drug, as showed by the FTIR analysis. 
However the process utilized requires the evaporation of the solvent overnight, and 
lyophilization of these NPs is a relatively slow and energy-consuming process.  
The main objective of this chapter was to focus on the nano-encapsulation of LAM 
into PCL NPs using the double emulsion spray-drying method. Controlled release 
may be achieved as the polymer degrades, resulting in a decreased frequently 
administration of the drug due to increased half life. Thus simultaneously minimizing 
side effects associated with LAM. Formulation parameters such as the effect of 
solvent, excipient and drug concentration were optimized for the synthesis of LAM 
loaded-PCL (PCL-LAM) NPs.  
Preparation of spray-dried NPs is an attractive alternative to freeze-drying method, 
since it offers the advantage of being a single-step process (Baras et al., 2000). In 
addition, it can be easily scaled up, and has been used in the pharmaceutical 
industries for the formation of NPs and microparticles (Broadhead et al., 1992). PCL 
polymer is known with its superior rheological and viscoelastic properties over many 
biodegradable polyesters, which renders PCL easy to manufacture (Woodruff and 
Hutmacher, 2010). Consequently PCL displays more advantageous features and it is 
less expensive when compared to other polyesters like PLA (Dash et al., 2011) 
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3.2 Materials and methods 
3.2.1. Materials 
PCL with average molecular weight number 10 000, polyvinylalcohol (PVA) 
molecular weight 13,000-23,000 (87-89% hydrolyzed) were obtained from Sigma-
Aldrich (South Africa). LAM drug was commercially purchased from Aspen 
Pharmacare (South Africa). The organic solvents, EA and DCM were also purchased 
from Sigma-Aldrich. Two excipients i.e. lactose monohydrate and trehalose 
(anhydrous) were obtained from Sigma-Aldrich and Merck (South Africa) chemicals, 
respectively. Ultra purified water (resistivity higher than 18.2M_cm) was used 
throughout and all other chemicals were of analytical grade. 
3.2.2. Synthesis of PCL-LAM NPs 
PCL-LAM NPs were prepared using the modified double emulsion spray-dried 
method as shown in Fig.3.1, discussed in our previous work (Semete et al., 2010). 
Briefly, 2 ml of an aqueous solution of 2% PVA containing LAM drug was emulsified 
for 3 minutes with a solution of 100 mg PCL dissolved in 8 ml of solvent (EA or DCM 
or either a mixture of DCM and EA), by means of a high speed homogeniser 
(Silverson L4R GX-10 model, Silverson Machines Limited, United Kingdom) with a 
speed varying between 3000 and 5000 rpm to form a water-in-oil emulsion (w/o). 
The resulting emulsion was transferred into a specific volume of aqueous solution 
containing 2% PVA, 0.5% PEG, 5% lactose or 5% trehalose, and 0.3% chitosan. The 
mixture was homogenised for 5 minutes at 8000 rpm to form water-in-oil-in-water 
(w/o/w) emulsion. The prepared nano-emulsion was fed into the spray dryer (model 
B-290, Buchi labortechnik AG, Switzerland) to obtain the PCL-LAM NPs. The PCL-
LAM NPs were collected and kept in the dessicator at room temperature. All 
experiments were performed in triplicate Standard spray drying conditions were: inlet 
temperature 96oC, aspirator setting, 100%, pressure 7 bars, with an achieved outlet 
temperature of 65oC to 70oC 
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Figure 3.1: Schematic representation of the flow chart showing the production of 
PCL-LAM NPs by the double emulsion spray-drying method. 
3.2.3. Particle size, particles size distribution and zeta potential 
Mean average particle size and particle size distribution of the spray-dried NPs was 
measured using Malvern Zetasizer Nano ZS (Malvern Instruments, United Kingdom). 
The weight product of the PCL-LAM NPs was suspended in deionised water by 
sonication. Zeta potential (ZP) was also determined using the same method and 
instrument. Each sample was measured in triplicates and the results are expressed 
as mean ± standard deviation (SD) 
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3.2.4. Drug content of NPs 
The encapsulation efficiency (EE) of the PCL-LAM NPs was determined using UV-
visible spectrophotometer (Perkin Elmer, Lambda 35, Singapore). In brief, 20 mg of 
the PCL-LAM NPs were dispersed in 10 ml deionised water and sonicated to obtain 
a homogenous particle distribution. The sample was centrifuged and the supernatant 
was then analyzed by UV. Each sample was measured in triplicates and. the results 
are expressed as mean ± SD 
 The EE was calculated using the following equation: 
 
and is defined by the ratio of measured and initial amount of the drug encapsulated 
in the NPs. Drug loading of the NPs was found using the ration of measured amount 
of drug encapsulated and amount of drug recovered or amount of NPs collected.  
3.2 5. Fourier transmission infra red spectroscopy (FTIR) 
The FTIR spectrum of the pure PCL polymer, pure LAM drug, PCL-LAM and drug 
free PCL NPs (PCL-DF) (used as a control) were obtained using Perkin Elmer 
spectrum 100 FTIR (spectrophotometer, USA). The samples were placed onto FTIR 
plate for measurements. The spectrum was recorded with wavenumbers between 
4000 cm-1 and 650 cm-1. 
3.2.6. Scanning electron microscopy (SEM)  
The morphology of the PCL-LAM and PCL-DF NPs was analyzed using SEM (Field 
Emission Electron Microscope, JEOL JSM-7500F, Japan). The NPs were mounted 
onto carbon stubs using a double sided carbon adhesive tape and sputtered with 
conductive gold in a high vacuum evaporator under an argon atmosphere prior to 
imaging.  
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3.2.7. X-ray diffraction (XRD)  
XRD measurements of pure PCL polymer, pure LAM drug, PCL-DF and PCL-LAM 
NPs were carried out using Phillips X’Pert PRO diffractometer from PANalytical 
(Netherlands) under reflection–transmission mode. Samples were placed in glass 
sample holders and scanned from 2 = 5o to 60o, using a beam of Cu K  radiation 
of  = 0.1542 nm, operated at 45 kV, 40 mA. The scan speed and exposure time 
were 0.109419 º/s and 17 min 27 s, respectively. 
3.2.8. Differential scanning calorimetry (DSC) 
DSC measurements of pure PCL polymer, pure LAM drug, PCL-DF and PCL-LAM 
NPs were carried out on TA Instrument (DSC Q 2000, USA). Samples with sizes 
ranging from 2 to 6 mg were accurately weighed into standard aluminum pans. DSC 
study was performed at heating rate of 10 oC/min from – 100 to 250 o C under 
nitrogen atmosphere with a flow rate of 50 mL.min-1. An empty aluminum pan was 
used as a reference. 
3.2.9. Thermogravimetric analysis (TGA) 
TGA of pure PCL polymer, pure LAM drug, PCL-DF and PCL-LAM NPs were 
characterized using from TA Instrument (TGA Q 500, USA), using balance and 
sample purge nitrogen gas of 30 and 60 ml/min respectively. Sample weights 
between 5 and 12 mg were used and placed into open aluminium pans. A heating 
rate of 10 oC/min was implemented, with a heating ramp from room temperature to 
700 o C 
3.2.10. In vitro EFV release from PCL NPs 
The in vitro drug release tests were carried out on PCL-LAM nanoparticles. Briefly, 
30 mg of PCL-LAM sample was suspended in 10 ml of PBS at various pH (1.3, 4.5 
and 6.8) at 37 0C and placed in a water bath shaker at 100 rpm. At predetermined 
time intervals, 1.5 ml of aliquots was withdrawn and the concentration of drug 
released was monitored by UV spectrophotometer (Perkin Elmer, Lambda 35, 
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Singapore). The dissolution medium was replaced with fresh buffer to maintain the 
total volume. Each sample was measured in triplicates and. the results are 
expressed as mean ± SD The drug release percent can be determined by the 
following equation 
 
Drug release (%) = C (t)/C (0) × 100 
3.2.11. Stability study 
The stability of the developed PCL-LAM NPs formulation was evaluated for 1 year. 
Briefly, samples were stored in the sealed amber colored glass vials and kept in 
dessicator at room temperature. After 1 year, the samples were characterized with 
respect to mean particle, PDI, ZP and EE 
3.3 Results and discussion 
3.3.1. Effect of process parameters 
The aim of the present study was to investigate double emulsion spray-drying 
process for the production of PCL-LAM NPs. The effect of different processing 
parameters on the particle size, particle size distributions as PDI and ZP are 
discussed in the following sections. 
3.3.1.1. Effect of solvent on particle size and particle size distribution 
In the present section, organic solvents namely DCM, EA and their mixtures were 
used as an organic phase during NPs preparation. The concentration of the polymer 
and the drug were kept at a constant ratio of 1:1 i.e. 100 mg of PCL and LAM. The 
basic principle for preparation of NPs by double emulsion spray-drying method is 
that the solvent in the organic phase normally dissolves in the aqueous phase by 
means of emulsification and then evaporated by the spray-drier (discussed in 
Chapter 1). The rate of emulsification and extent of organic phase to associate with 
aqueous phase depend on the solubility of the solvent (Chernysheva et al., 2003; 
Song et al., 2006; Luong-Van et al., 2007). Table 3.1 shows a summary of the 
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solubility of DCM, EA in aqueous phase, and or that of PCL in DCM and EA (Song et 
al., 2006; Woodruff and Hutmacher, 2010). The difference between DCM and EA is 
that DCM is immiscible in aqueous phase but EA is partially soluble (Song et al., 
2006).  
Figure 3.2 shows the mean particle size and PDI of the prepared PCL-LAM NPs. 
PCL-LAM NPs of approximately 214.7±3.05 nm and 277.1±27.57 nm were obtained 
when partially water soluble solvent EA was used. PCL-LAM NPs ranging from 
454.4±11 nm to 604.3±8.46 nm in mean particle size were obtained when DCM was 
used, and also the mixture of DCM with EA yielded large NPs. 
Table 3.1: Solubility of organic phase in aqueous phase (AP), and PCL in organic 
phase solvents 
 EA DCM 
AP Slightly soluble (10% (v/v) at 25oC Immiscible (2% (v/v) at 25oC) 
PCL Good solvent Excellent solvent 
 
This means that the solubility of organic solvent phase plays an important major role 
in the mean particle size of the obtained PCL-LAM NPs. The rate of organic phase 
containing a polymer with an aqueous phase followed by the evaporation of the 
solvent is a key parameter which controls the size of the NPs (Maia and Santana, 
2004; Jyothi et al., 2010). DCM is immiscible in water, displaying non-significant 
adsorption at the organic/aqueous phase boundary resulting in higher interfacial 
tension, causing agglomeration to occur (Chernysheva et al., 2003; Song et al., 
2006). Small mean+ particle sizes for EA were attributed to low interfacial tension 
between organic and aqueous phase, resulting from partially solubility nature of the 
solvent (Song et al., 2006). EA diffuses quickly out of the polymer, explaining the 
less importance of agglomeration. All the NPs prepared with DCM and DCM/EA 
mixture as solvents were not homogeneous with PDI ranging from 0.44±0.04 to 
0.48±0.07, however PCL-LAM NPs prepared with EA only had good PDI of 
0.23±0.01 to 0.42±0.04. The obtained results are also showed graphically in Fig. 3.3. 
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Figure 3.2: Properties of PCL-LAM NPs (data represent mean ± SD, n = 3) 1 = DCM 
used as solvent, 2 = EA used as a solvent, 3= mixture of DCM and EA, a = lactose 
used as excipient, and b = trehalose used as excipients. 
. 
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Figure 3.3: Mean particle size and particle size distribution of the PCL-LAM NPs. 
Each color indicates different runs. A = DCM as solvent, lactose as excipient, B = EA 
as solvent, and lactose as excipient, C = DCM/EA mixture and lactose as excipient, 
D = DCM as solvent, trehalose as excipient, E = EA as solvent, and trehalose as 
excipients, F = DCM/EA mixture and trehalose as excipient 
  
D 
F 
E 
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ZP is an important parameter, which can predict the physical stability of the 
nanodispersion. It also indicates the degree of repulsion between similar charged or 
close particles in the nanodispersion. Moreover, it could govern the interaction with 
cells. Whether positive or negative, higher values of the ZP show that the particles 
generally prevent agglomeration due to electric repulsion. According to the literature, 
ZP of more than ±13.01 mV indicates stable NPs (Das et al., 2011). The overall NPs 
had higher positive surface charge, ranging from +17.8±2.75 mV to+22.8±0.95 mV 
indicating that PCL-LAM NPs might be stable. The positive surface charge of our 
NP’s is attributed to the chitosan added in the formulation during preparation ( see 
method section). Chitosan is able to open the tight junctions and in this way allows 
paracellular transport across the epithelium. According to the literature, it is reported 
that both  nasal  and  oral  drug delivery  research  has  showed  that  signiﬁcantly  
higher amounts of drugs  can  be  transported after  co-administration with chitosan 
(Inez et al., 2003) 
3.3.1.2. Effect of excipients 
The objective of the present section was to investigate the effect of the different 
excipients on the properties of the spray-dried PCL-LAM NPs. For this purpose, 
different formulations involving two of the most commonly used excipients in the 
preparation of the spray-dried NPs or microparticles were used i.e. lactose and 
trehalose (Arpagaus et al, 2010). These excipients are approved by the US-FDA, 
due to their non-toxicity and readily degradable properties after administration 
(Arpagaus et al, 2010). The inclusion of these excipients in the formulation is of 
importance, since PCL polymers exhibits low melting temperatures (Tm), low glass 
transition temperatures (Tg) of 54
oC to 64oC and -60oC, respectively (Woodruff and 
Hutmacher, 2010). Thus the process with the spray drying must be carried at low 
inlet temperatures to avoid the sticking problems. Recently Kho and co-workers 
showed that the formation of the PCL NPs without adding excipients, resulted in the 
collection of the polymer films on the drying chamber and walls of the cyclone (Kho 
et al., 2010).  
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Lactose has the valuable material property of a low stickiness behavior compared to 
other sugars like sucrose, glucose and maltose (see Table 3.2). Moreover the higher 
the Tg of 101
oC enables a simple flowing powders during spray-drying process. 
Trehalose has a higher Tg when compared to glucose and sucrose (Simplerler et al., 
2006). The Tg of trehalose falls between 75 and 120
oC according to the literature 
(Rose and Labuza, 2005), and Tm of trehalose is 210.5
oC (Higashiyama, 2002), 
nearly close to that of lactose (223oC). 
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Table 3.2: Comparison of physical properties of different sugars and relative stickiness behavior (Arpagaus et al, 2010) 
Sugar Hygroscopicity 
(relative) 
Melting 
(oC) 
Water solubility at  
60oC (w%) 
Tg (
 oC) Stickiness 
(relative) 
Lactose + 223 35 101 + 
Maltose ++ 165 52 87 ++ 
Sucrose +++ 186 71 62 +++ 
Glucose +++++ 146 72 31 +++++ 
Fructose ++++++ 105 89 5 ++++++ 
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Figure 3.2 shows the mean particle size, PDI when lactose and trehalose were used, 
respectively in A and B. Results indicated that small PCL-LAM NPs ranging from 
214.7±3.05 nm to 552.6±8.46 nm were formed when lactose was used as excipient 
and large PCL-LAM NPs ranging from 277.1±27.57 nm to 604.3±8.46 nm were 
obtained with trehalose.  All NPs prepared with lactose had at least minimum PDI of 
0.23±0.01 to 0.48±0.07, and trehalose produced PDI ranging from 0.42±0.04 to 
0.47±0.07 (also represented graphically in Fig. 3.3). The overall NPs prepared in the 
presence of lactose and trehalose had higher positive surface charge ranging from 
+18±1.48 mV to +22.8±0.95 mV for lactose and +18.3±0.56 mV to +19.9±0.96 mV 
for trehalose, indicating that PCL-LAM NPs might be stable. These results show that 
lactose is a good excipient in the formulation of spray-dried PCL-LAM NPs. This 
might be due to higher Tm of lactose when compared to that of trehalose. 
3.3.2. The effect of drug concentration on EE of PCL-LAM NP 
The previous sections showed that a partially water soluble solvent EA and lactose 
as excipient, are good candidates on the preparation of PCL-LAM NPs, as a results 
there were further selected to produce NPs. The amount of the PCL organic solvent, 
and lactose were kept constant, only the amount of LAM was assessed on the effect 
of mean particle size, PDI, ZP, EE, and the results are shown in Fig. 3.4. There were 
insignificant differences in mean particle size among different NPs prepared with 
LAM drug ranging from 50 to 75 mg. The mean particle sizes obtained were 
243.6±3.07 nm, 252±5.17 nm for 50 mg LAM and 75 mg LAM, respectively. The 
mean particle size decreased with increasing the amount of drug to 100 mg with the 
value of 214.7±3.05 nm. PCL-DF NPs were also prepared as control, and showed 
the mean particle size of 233.9±3.36 nm. Figure 3.4 shows the mean particle size 
and PDI of the prepared NPs. From the Fig.3.4 it can be concluded that the NPs had 
good PDI. The PDI values obtained were 0.165±0.01, 0.205±0.02, 0.227±0.01 for 
PCL-LAM (50 mg), PCL-LAM (75 mg), PCL-LAM (100 mg) NPs, respectively, and 
0.155±0.02 for PCL-DF NPs. These results indicate that PDI was increasing with the 
increase of amount of drug in the formulation. EE was found to decrease with 
increasing the amount of LAM drug. PCL-LAM (50 mg) had higher EE of 
77.82±4.40%, while PCL-LAM (75 mg) and PCL-LAM (100 mg) had EE of 
71.48±6.10% and 64.21±4.0%, respectively. Moreover irrespectively of the amount 
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of drug nano-encapsulated in the formulation, drug loading was ranging from 20% to 
35%. ZPs were greater than +20 mV in all cases, which suggest good stability of the 
PCL-DF and PCL-LAM NPs 
 
Figure 3.4: Mean particle size, PDI and EE (%) of the prepared PCL-LAM NPs (data 
represent mean± SD, n = 3) a) 50 mg LAM, b) 75 mg LAM and c) 100 mg LAM on 
the formulation 
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Figure 3.5: The effect of LAM drug concentration on the mean particle size and PDI 
of the PCL-LAM NPs. A) PCL-DF nanoparticles, B) 50 mg LAM C) 75 mg LAM, D) 
100 mg LAM. 
3.3.3. Morphology of PCL-LAM NPs 
Figure 3.6 shows SEM images of the prepared PCL-LAM NPs. All PCL-LAM NPs 
prepared in the presence of lactose had spherical morphology, confirming the ability 
of lactose as a surface modifier and to enhance spherical morphology of the NPs 
(Takeuchi et al, 1998). Some PCL-LAM NPs prepared in the presence of trehalose 
showed the formation of crystals, these results also support that lactose was good 
drying excipient. 
Figure 3.7 shows PCL-LAM NPs, when EA and lactose were used only on the 
formulation. All PCL-LAM NPs had spherical morphology. No changes were 
observed when the amount of LAM drug was increased from 50 to 100 mg. PCL-DF 
NPs also showed spherical morphology. 
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Figure 3.6: SEM images: (A) PCL-LAM NPs with DCM and lactose, B) PCL-LAM NPs with EA and lactose, C) PCL-LAM NPs with 
DCM/EA and lactose, D) LPCL-LAM NPs with DCM and trehalose, E) PCL-LAM NPs with EA and trehalose, F) PCL-LAM NPs with 
DCM/EA and trehalose. 
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(C)              (D) 
Figure 3.7: SEM images when EA and lactose were used to prepare the NPs. A) PCL-DF NPs, B) PCL-LAM (50 mg) NPs C) PCL-
LAM (75 mg), D) PCL-LAM (100 mg) NPs. 
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3.3.4. Structural compositions of PCL-LAM NPs  
Structural compositions of the PCL-LAM NPs were investigated only on the ones 
prepared with partially water soluble solvent (EA), lactose as a excipient and PCL-
LAM (100 mg) NPs because they displayed more optimal properties. Pure PCL 
polymer and PCL-DF NPs were used as controls. An assessment on the FTIR 
analysis of pure PCL, PCL-DF and PCL-LAM NPs showed the characteristic peak of 
the PCL polymer (Figure 3.8) at around 1721.4 cm-1 and 1725.9 cm-1 due to the C=O 
stretching vibration (Wu, 2005; Sahoo et al., 2010) . LAM spectra presented two 
bands at 1634.46 cm-1 and 1605.24 cm-1, attributed to -C=O and -C=N, respectively, 
similar results were obtained by Dev and co-workers (Dev et al., 2010). The new 
peak on the PCL-LAM NPs was formed between 1750 cm-1 and 1600 cm-1. The peak 
shows the interaction between the PCL polymer and the LAM drug. In addition it 
confirms that the drug was nano-encapsulated onto the PNPs 
 
Figure 3.8: FTIR spectra of (A) pure PCL, (B) PCL-DF, (C) LAM drug, and (D) PCL-
LAM NPs. 
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3.3.5. X-ray diffraction 
The powerful tool of showing the crystalline and amorphous region is the use of XRD 
spectroscopy. Figure 3.9 present the XRD patterns of pure PCL polymer, LAM drug, 
PCL-DF and PCL-LAM (100 mg) NPs. The polymer presented two sharp peaks at 
around 21.3o and 23.9o which are due to scattering from crystalline region and the 
underlying “hump” in red are due to scattering from the amorphous region (Young 
and Lovell, 1991), a similar spectra was also reported by (Wu, 2005). The XRD 
patterns of LAM presented multiple sharp peaks showing the crystalline nature of the 
drug. However the XRD patterns of the spray dried PCL-DF and PCL-LAM NPs were 
characterized by broad hump and the absence of any sharp peaks over the entire 2 
theta, which is an indicative of their amorphous nature.  
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Figure 3.9: X-ray diffraction patterns of (A) PCL-LAM NPs, (B) PCL-DF NPs,(C) 
LAM drug, and (D) pure PCL. 
3.3.6. Thermal analysis 
Thermal analysis (TA) is a very useful method for evaluating drug-polymer 
interactions, to assess the influence of excipients and micro- or nano-encapsulation 
process on the physico-chemical properties of pharmaceutical materials (Gaisford 
&Buckton, 2001;Silva-Junior et al, 2008).DSC and TGA are the most frequently used 
thermoanalytical technique among the TA. DSC can be used to measure enthalpy 
changes due to changes in the physico-chemical properties of the material as a 
 74 
function of time or temperature, while TGA can provide mass loss as a function of 
temperature (Han & Suryanarayanan, 1999; Horvat et al., 2005; Coughlan & 
Corrigan, 2006). Thus, both techniques can provide qualitative and quantitative 
information about the physical and chemical properties of the drug in the NPs (Silva-
Junior et al., 2009). 
The DSC curve comprises of 3 stages, the first heating scan, controlled cooling 
(known as crystallization) and second heating scan. Second heating is important as 
it shows only characteristics properties of the materials after controlled cooling; 
conversely first heating it shows the current specimen condition i.e. thermal and 
mechanical history + characteristics properties of the materials before cooling. 
However for the purpose of the study, second heating was chosen as it concentrates 
only on the polymer (PCL) and the drug not excipients used (Ehrenstein et al., 2004). 
The DSC curve for LAM drug (Fig.3.10) shows the endothermic peak in the range of 
177.56oC (enthalpy change of 119.5 J/g), due to sample dehydration, which was 
confirmed by a weight loss of 52.78% verified in the range of 186.40oC to 246.58oC 
in the TGA curve (Fig. 3.11), similar results were obtained with other spray dried NPs 
using different materials (Silva-Junior et al, 2008).  
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Figure 3.10: DSC curve of LAM drug in a dynamic nitrogen atmosphere, at a heating 
rate of 10oC/min. 
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Figure 3.11: TGA curve for LAM drug in a dynamic nitrogen atmosphere, at a 
heating rate of 10oC/min. 
DSC second heat of pure PCL, PCL-DF NPs and PCL-LAM (100 mg) NPs are 
presented in Fig. 3.12.Table 3.3 summarizes the final melting temperatures and 
enthalpy changes of the thermograms. Pure PCL polymer showed the Tm of 
53.44oC, while PCL-DF NPs and PCL-LAM (100 mg) NPs showed the Tm of 54.80
oC 
and 55.24oC, respectively, which are all nearly similar to the theoretical value 
reported (Woodruff and Hutmacher, 2010). Moreover the Tg of the pure PCL, PCL-
DF NPs and PCL-LAM (100 mg) NPs was found to be at -60oC, similar to the 
reported value (Woodruff and Hutmacher, 2010). These results suggest that the 
double emulsion spray-drying method did not affect the melting properties of the 
polymer. However, the enthalpy decreased drastically when the polymer was 
processed with the double emulsion spray-drying method, and it further decreased to 
a lower value when the LAM was nano-encapsulated into the PCL-NPs. The Gibbs 
free energy (G) of any system is given by (Young and Lovell, 1991): 
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G= H - TS          (1) 
H= G +TS          (2) 
where H is the enthalpy, S is the entropy, and T is the thermodynamic temperature. 
A decrease in enthalpy change causes the entropy of the system to become small 
(see Figure 3.13), leading to higher values of G (Young and Lovell, 1991). The 
higher values of G cause the material to be amorphous (Young and Lovell, 1991).  
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Figure 3.12: DSC thermograms of (A) pure PCL, (B) PCL-DF NPs, and (C) PCL-
LAM NPs. in a dynamic nitrogen atmosphere, at a heating rate of10oC/min.Second 
heating. 
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Table 3.3: Melting temperature and enthalpy change of PCL, PCL-DF NPs and PCL-
LAM NPs from DSC thermograms. Second heating scan.  
Materials Final temperature  
Tm (
oC) 
Enthalpy Change  
J/g 
Pure PCL 53.44 76.90 
PCL-DF NPs 54.80 8.60 
PCL-LAM NPs 55.24 7.77 
 
DSC was further used to investigate the crystalline nature of the prepared PCL-LAM 
NPs. Figure 3.13 shows the DSC thermogram of pure PCL polymer, PCL-DF and 
PCL-LAM (100 mg) NPs. In agreement with the XRD analysis, the DSC data 
corresponding to the cooling temperature showed no Tc after the spray dried process 
was carried out for both the PCL-DF and PCL-LAM (100 mg) NPs due to the 
absence of exothermic peak after cooling, supporting that our NPs are amorphous. 
Pure PCL polymer had a sharp exothermic peak, showing the crystalline nature of 
the polymer. 
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Figure 3.13: DSC thermograms of (A) pure PCL (B) PCL-DF, and (C) PCL-LAM NPs 
in a dynamic nitrogen atmosphere, at a heating rate of10oC/min. Cooling 
temperature. 
Figure 3.14 presents the TGA thermograms of the pure PCL, PCL-DF and PCL-LAM 
NPs. TGA curve of pure PCL showed that polymer was thermally stable until 
136.27oC. The weight loss of PCL polymer occurred in 3 steps at temperature of 
345.09oC, 428.64oC and 509.48oC with a weight loss of 12.24%, 84.28% and 2.89%, 
respectively, attributed to thermal decomposition. Both the PCL-DF and PCL-LAM 
NPs showed low thermal stability when compared to the pure PCL polymer. This 
may be due to the fact that the NPs have a greater superficial area, since there are 
more reactive than the polymer; consequently the thermal decomposition tends to 
occur much faster (Mainardes et al, 2006). 
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The residual moisture of the PCL-DF and PCL-LAM NPs was ranging from 4.289 to 
4.261%, respectively. The results obtained are in agreement with the reported values 
of spray-dried particles, which range from 2% to 15% (Arpagaus et al., 2010). 
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Figure 3.14: TGA thermograms of (A) pure PCL, (B) PCL-DF NPs, and (C) PCL-
LAM NPs in a dynamic nitrogen atmosphere, at a heating rate of10oC/min. 
3.3.7. Drug release of the PCL-LAM NPs 
Figure 3.15 shows the drug release rate of the PCL-LAM (100 mg) NPs suspended 
in media of various pH values i.e. 1.3, 4.5 and 6.8. After 8 hours, LAM drug 
concentration in buffer came around 39.0%, 38.6% and 44.0% at pH 1.3, 4.5 and 
6.8, respectively. The obtained results demonstrate that drug release rate was 
increasing as the pH approaches the alkaline media. The release of the drug from 
polymer NPs can be affected by many factors such as polymer degradation, 
molecular weight of the polymer, crystalinity, the binding affinity between the polymer 
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and the drug (Shin et al., 1998). The lower drug release rate in the pH 1.3 and pH 
4.5 than pH 6.8 is attributed to the repulsion between H+ and cations on the surface 
of the PCL-LAM NPs by superficial chitosan layers, which slow down the hydrolysis. 
The PCL-LAM NPs were coated with chitosan. 
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Figure 3.15: Drug release rate of PCL-LAM NPs. (A) pH 1.3, (B) pH 4.5, and (C) pH 
6.8. 
3.3.8 Physical stability 
The dry state (not in a suspension) PCL-LAM (100 mg) NPs showed no changes of 
the mean particle size, PDI, ZP and EE, when stored at 25oC in a dessicator. The 
results (214.7±3.05 nm, 0.227±0.01, 22.9±0.50 mV and EE of 64.21±4.0%) indicated 
good physical stability of PCL-LAM (100 mg) NPs. 
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3.4 Conclusions 
Double emulsion spray-drying process resulted in the formation of small mean 
particle size with good PDI, spherical morphology when EA and lactose were used 
as organic and excipient respectively. However when DCM, a mixture of DCM/EA 
solvent and trehalose used as excipient large nanoparticles were obtained with poor 
PDI. These highlighted that DCM is not a good solvent for the preparation of PCL-
LAM nanoparticles Different characterization methods employed in these work 
showed that, the process did not affect the properties of the drug and the polymer, 
after the spray-drying method. The process parameters utilized in this study helped 
to convert the crystalline drug and semi-crystalline polymer into the amorphous form, 
and a drug was released into PCL polymer for more than 24 hours, unlike the half life 
of 5 to 7 hours when compared to the LAM free drug 
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CHAPTER 4:  
NANO-ENCAPSULATION OF WATER INSOLUBLE DRUG, 
EFAVIRENZ USING A DOUBLE EMULSION SPRAY DRYING 
TECHNIQUE FOR IMPROVING HIV TREATMENT 
 
 
4.1 Introduction 
It is estimated that nearly 40% of new chemical entities (NCE) particularly belonging 
to BCS class II and IV suffers from solubility issues, thus posing major challenges to 
the pharmaceutical industries to engage strategies that can increase the solubility of 
therapeutic agents (Wong et al, 2006; Kesisoglou et al, 2007; Vasconcelos et al, 
2007; Sachs-Barrable et al, 2008). In the recent years, nanotechnology has put 
many technological platforms in order to develop strategies that can increase 
solubility of these NCE. Biocompatible and biodegradable polymers have a 
widespread potential as preferred candidate to nano-encapsulate hydrophobic drugs 
due to the presence of protective shell that can be functionalized to enhance the 
solubility and stability of the drugs from physiological conditions. Moreover these 
systems features advantage such as good releasing properties as the polymer 
degrade. 
EFV, chemically described as (S)-6-chloro-(cyclopropylethynyl)-1, 4-dihydro-4-
(trifluoromethyl)-2H-3, 1-benzoxazin-2-one is a NNRTI (Michael et al., 2002; 
Chippetta et al., 2010), approved for the treatment of HIV-1 virus, and used with 
other ARVs in a combination treatment (Neves et al, 2010). EFV is the favoured drug 
by the British HIV Association, the U.S Department of Health and Human Services 
and the International AIDS Society, also it is the first choice in pediatric treatment 
(children above the age of 3 years) (Dybul et al., 2002; Hammer et al., 2006; 
Williams et al., 2011). However EFV is a hydrophobic crystalline drug suffering from 
low intrinsic aqueous solubility of 4 µg/ml, which leads to a limited oral absorption 
and low bioavailability (40–45 %) (Chiappetta et al., 2011).The daily suggested dose 
of 200 mg to 600 mg is required daily for life time. The oral administration of EFV 
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exhibits abnormal thinking, confusion, depression, hallucinations, memory loss, 
paranoid thinking, and thoughts of suicide.  
Shown et al. demonstrated the inclusion of EFV into the lactose based oligomers of 
β- cyclodextrins to improve the solubility of EFV (Shown et al., 2010). Findings 
showed that the EFV was absent on the surface of the prepared NPs when FTIR 
was used, suggesting that EFV was nano-encapsulated inside the oligomeric chains. 
They also showed that the prepared NPs were stable and amorphous compared to 
the free “naked” drug when TGA and XRD were used, respectively. In another 
interesting study by Chiappetta et al, they loaded EFV into polymeric micelles of 
Pluronic® F127 to increase the solubility and bioavailability of the drug (Chiappetta 
et al., 2010). The prepared micelles were compared to that of a suspension with the 
content of EFV capsules in 1.5 % carboxymethylcellulose PBS solution and EFV 
solution prepared in medium-chain triglyceride (MCT). The results showed that the 
solubility of the drug was increased, bioavailability of the prepared micelles led to 
higher plasma concentrations and plasma level areas under the curve that were 
greater than that of EFV prepared in a buffer and one in MCT. 
The main focus of this work was to nano-encapsulate EFV into PCL polymer using 
double emulsion spray-drying method. The nano-encapsulation of EFV into 
biodegradable and biocompatible PCL polymer using the scalable double emulsion 
spray drying method is seldom or has never been published in the literature. Yang et 
al. formulated the amorphous solid dispersion of EFV using the spray-drying method 
and polyvinylpyrrolidone (PVP) polymer. This study is of great value since the 
amorphous drug-polymer solids have higher solubility, higher dissolution and the 
potential of improving bioavailability (Yu, 2001; Hancock, 2002; Ahuja et al., 
2007).We therefore envisaged that by nano-encapsulation of EFV into PCL NPs, 
drug release can be prolonged, since PCL degrade slower as compared to other 
biodegradable and biocompatible polyesters (Sinha et al., 2004), solubility of the 
drug can be achieved and this property can ultimately increase the bioavailability of 
the drug. 
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4.2. Materials and methods 
4.2.1. Materials 
PCL with average molecular weight number 10,000 g/mol, polyvinylalcohol (PVA) 
molecular weight 13,000–23,000 g/mol (PVA, 87-89 % hydrolyzed) were obtained 
from Sigma-Aldrich (South Africa). EFV drug was commercially purchased from 
Aspen Pharmacare (South Africa). The organic solvents, EA and DCM were also 
purchased from Sigma-Aldrich. The drying excipients lactose monohydrate (water 4 
– 6 %) and trehalose were obtained from Sigma and Merck Chemicals respectively 
(Johannesburg, South Africa). All other chemicals and solvents were of analytical 
grade and used as obtained. 
4.2.2. Synthesis of EFV-loaded PCL NPs (PCL-EFV) 
PCL-EFV NPs were prepared using the modified double emulsion spray dried 
method previously reported (Fig. 4.1) (Semete et al., 2010). Briefly, 2 ml of an 
aqueous solution of 2 % PVA containing stabilizers was emulsified for 3 minutes with 
a solution of 100 mg PCL and EFV, dissolved in 8 ml of solvent (EA or DCM or either 
a mixture of DCM and EA), by means of a high speed homogenizer (Silverson L4R 
GX-10 model, Silverson Machines Limited, United Kingdom) with a speed varying 
between 3000 and 5000 rpm to form the w/o emulsion. The resulting emulsion was 
transferred into specific volume of aqueous solution containing 2% PVA, 0.5% PEG, 
5% lactose or 5% trehalose, and 0.3% chitosan. The mixture was homogenised for 5 
minutes at 8000 rpm to form the w/o/w emulsion. The prepared emulsion was fed 
into spray-dryer (model B-290, Buchi labortechnik AG, Switzerland) to obtain the 
solid PCL-EFV NPs that were collected and kept in the dessicator at room 
temperature. Standard spray drying conditions were: inlet temperature 96oC, 
aspirator setting, 100%, pressure 7 bars, with an achieved outlet temperature of 65 
to 70oC.  
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Figure 4.1: Schematic representation of the flow chart showing PCL-EFV NPs by 
double emulsion spray-dried method. 
4.2.3. Particle size, PDI and zeta potential 
Mean average particle size and PDI of the PCL-EFV NPs was measured using 
Malvern Zetasizer Nano ZS (Malvern Instruments, United Kingdom). The weight 
amount of the PCL-EFV NPs was suspended in deionised water by sonication. Each 
sample was measured in triplicate. Zeta potential was also determined using the 
same method and instrument. 
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4.2.4. Drug content of nanoparticles 
The drug loading and EE of PCL-EFV NPs was determined using UV-Visible 
spectrophotometer (Perkin Elmer, Lambda 35, Singapore). In brief, a required 
amount of the PCL-EFV NPs were dispersed in 10 mL deionised water and 
vigorously vortexed to disperse the NPs. The sample was centrifuged and the 
supernatant was then analyzed by UV. Each sample was measured in triplicate. The 
encapsulation efficiency was calculated using the following equation: 
 
and is defined by the ratio of measured and initial amount of the drug encapsulated 
in the NPs. Drug loading of the NPs was found using the ration of measured amount 
of drug encapsulated and amount of drug recovered or amount of NPs collected 
4.2.5. Fourier transmission infra red spectroscopy (FTIR) 
The FTIR spectrum of the pure PCL polymer, pure EFV drug, PCL-DF and PCL-EFV 
were obtained using Perkin Elmer spectrum 100 FTIR spectrophotometer. The 
samples were placed onto FTIR plate for measurements. The spectrum was 
recorded with wavenumbers beginning from 4000 cm-1 to 650 cm-1. 
4.2.6. Scanning electron microscopy (SEM) 
The morphology of the PCL-EFV and PCL-DF NPs were characterized using a SEM 
(Field Emission Electron Microscope, JEOL JSM-7500F, Japan). The NPs were 
placed onto carbon stubs using a double sided carbon adhesive tape and sputtered 
with conductive gold in a high vacuum evaporator under an argon atmosphere prior 
to imaging.  
4.2.7. X-ray diffraction (XRD) 
XRD analysis of pure PCL polymer, pure EFV drug, PCL-DF and PCL-EFV NPs 
were conducted using Phillips X’Pert PRO diffractometer from PANalytical 
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(Netherlands) under reflection–transmission mode. Samples were placed in glass 
sample holders and scanned from 2 = 5o to 60o, using a beam of Cu K  radiation 
of  = 0.1542 nm, operated at 45 kV, 40 mA. The scan speed and exposure time 
were 0.109419º/s and 17 min 27s, respectively. 
4.2.8. Differential scanning calorimetry (DSC) 
DSC measurements of pure PCL polymer, pure EFV drug, PCL-DF and PCL-EFV 
NPs were carried out on TA Instrument (DSC Q 2000, USA). Samples with sizes 
ranging from 2 to 6 mg were accurately weighed into standard aluminum pans. DSC 
study was performed at heating rate of 10oC/min from 100 to 250oC under nitrogen 
atmosphere with a flow rate of 50 mL.min-1. An empty aluminum pan was used as a 
reference. 
4.2.9. Thermogravimetric analysis (TGA) 
TGA of pure PCL polymer, pure EFV drug, PCL-DF and PCL-EFV NPs was 
performed using Q 500 from TA Instruments (TGA Q 500, USA), using balance and 
sample purge nitrogen gas of 30 and 60 ml/min respectively. Sample weights 
between 5 and 12 mg were used and placed into open aluminium pans. A heating 
rate of 10oC/min was implemented, with a heating ramp from room temperature to 
700 o C 
4.2.10. In vitro EFV release from PCL NPs 
The in vitro drug release tests were carried out on PCL-EFV (100 mg)) prepared with 
water soluble solvent EA and lactose (drying excipient). 30 mg of PCL-EFV sample 
was suspended in 10 ml of phosphate buffer solution (PBS) at various pH (1.3, 4.5 
and 6.8) at 370C and placed in a waterbath shaker at 100 rpm. At predetermined 
time intervals, 1.5 ml of aliquots was withdrawn and the concentration of drug 
released was monitored by UV spectrophotometer (Perkin Elmer, Lambda 35, 
Singapore). The dissolution medium was replaced with fresh buffer to maintain the 
total volume. The drug release percent can be determined by the following equation: 
Drug release (%) = C (t)/C (0) × 100 
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4.2.11. Stability study 
The stability of the developed PCL-EFV NPs formulation was evaluated for 1 year. 
Briefly, samples were stored in the sealed amber colored glass vials and kept in 
dessicator at room temperature. After 1 year, the samples were characterized with 
respect to mean particle, PDI, ZP and EE. 
4.3. Results and discussion 
4.3.1. Effect of process parameters on formulation characteristics 
The present study aims to investigate the effect of different process parameters on 
the formulation characteristics (i.e. mean particle size, PDI) of PCL-EFV NPs.  
4.3.1.1. Effect of solvent on particle size and particle size distribution 
The aim of the current study was to investigate the effect of solvents, namely DCM, 
EA and their mixtures on the preparation of PCL-EFV NPs. As discussed in Chapter 
3, DCM is immiscible in water and EA is partially soluble. Figure 4.2 and 4.3shows 
the effect of solvent on NPs mean particle size and particle size distribution. The 
concentration of the PCL polymer and EFV drug were kept at constant 
concentrations (1:1 ratio, 100 mg of PCL and of EFV). The mean particle size (n=3) 
of 217±2.48 nm and 247±3.20 nm were obtained when EA was used, while DCM 
produced large PCL-EFV NPs of 349±8.92 nm and 368.2±10.70 nm. Also the 
mixture of DCM with EA produced large mean particle size of 393±13.70 nm and 
448.4±.9.03 nm. The small mean particle size obtained with EA is due to low 
interfacial tension at organic/aqueous phase interface. The results are in accordance 
with data reported by other researchers (Song et al., 2006; Jyothi et al., 2010). All 
the NPs prepared with DCM, DCM/EA mixture as solvents had PDI ranging from 
0.379±0.05 to 0.42±0.01 and 0.323±0.01 to 0.470±0.01, respectively. They also 
presented a multiple narrow distribution, indicating that the PCL-EFV NPs prepared 
were not homogeneous. However PCL-EFV NPs prepared with EA showed a single 
narrow distribution, with PDI ranging from 0.093±0.02 to 0.125±0.05 indicating that 
NPs are homogenous. The overall PCL-EFV NPs had zeta potential ranging from 
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+14.5±0.15 mV to +23.1±0.35 mV, indicating that NPs might be physically stable in 
suspension. 
 
 
Figure 4.2: Properties of PCL-EFV NPs (data represent mean ± SD, n = 3) 1 = DCM 
was used as solvent, 2= EA was used as a solvent, 3= mixture of DCM and EA, a = 
lactose used as excipient, and b = trehalose used as excipient 
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4.3.1.2 Effect of excipients on particle size and particle size distribution 
The two excipients, namely lactose and trehalose were included in the formulation of 
PCL-EFV NPs. The inclusion of excipients in the formulation is of great value 
especially since PCL has a low Tg. The difference between lactose and trehalose are 
discused in Chapter 3. Results showed that small PCL-EFV NPs ranging from 
217±2.48 nm to 393.1±13.70 nm were obtained when lactose was used as an 
excipient given in Fig. 4.2A. Trehalose produced larger PCL-EFV NPs than lactose 
ranging from 247±3.20 nm to 448.4±9.03 nm, as depicted in Fig. 4.2B. The PCL-EFV 
NPs had good PDI ranging from 0.093±0.02 to 0.42±0.01 for lactose ( Fig 4.3 A-C), 
and 0.125±0.05 to 0.470±0.01 for trehalose (represented graphically in Fig. 4.3D-F). 
All PCL-EFV NPs were characterized by positive zeta potential ranging from 
+14.5±0.15 mV to +26±0.26 mV, suggesting that NPs might be stable 
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Figure 4.3: Mean particle size and particle size distribution of the PCL-EFV NPs A = 
DCM as solvent, lactose as excipient, B = EA as solvent, and lactose as excipient, C 
= DCM/EA mixture and lactose as excipient, D = DCM as solvent, trehalose as 
excipient, E = EA as solvent, and trehalose as excipients, F = DCM/EA mixture and 
trehalose as excipient 
4.3.2. The effect of drug concentration on EE of PCL-EFV NPs 
The previous section demonstrated that EA, the partially water soluble solvent and 
lactose used as excipient, showed smaller and better PDI results on the preparation 
of PCL-EFV NPs. This section focuses on the effect of drug concentration on the 
preparation of PCL-EFV NPs. The concentrations of organic solvent EA, containing 
the PCL polymer, and lactose were kept constant. Figure 4.4 presents the mean 
particle size, PDI, and EE of the obtained PCL-EFV NPs. Results showed that there 
were significant differences in mean particle sizes and PDI, when the amount of EFV 
was increased from 50 mg, 75 mg to 100 mg in the organic phase. The results 
obtained when changing the amount of EFV was 238.8±1.55 nm, 217.9±2.18 nm, 
207±2.48 nm, and PDI of 0.225±0.03, 0.147±0.02, 0.093±0.02, respectively. A 
decrease in mean average particle size might be due to the increase in the viscosity 
of the internal organic phase (Jyothi et al., 2010). In all formulations the EE was 
nearly the same and the obtained results are 94.8±2.10%, 93.6±1.10%, and 
93.1±3.03% for 50 mg, 75 mg and 100 mg EFV drug, respectively. Drug loading was 
ranging from 30% to 40% in all formulations.PCL-DF NPs had mean particle size of 
233.9±3.36 nm and PDI of 0.155±0.02, showing that EFV had a huge effect on the 
F 
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preparation. Figure 4.5 shows the mean particle size and PDI of the prepared NPs, 
from the Fig it can be concluded that the NPs were homogeneous. All PCL-EFV and 
PCL-DF NPs had higher ZP of more than +26±0.69 mV, suggesting that the 
prepared NPs might be physically stable (Das et al., 2011). 
 
Figure 4.4: Properties of PCL-EFV NPs (data represent mean ± SD, n = 3),a) 50 mg 
EFV, b) 75 mg EFV and c) 100 mg EFV on the formulation. 
 
 
 
 
 
 
 
 98 
 
  
 
A 
B 
C 
 99 
( 
Figure 4.5: The effect of EFV drug concentration on the mean particle size and PDI 
of the PCL-EFV NPs. A) PCL-DF nanoparticles, B) 50 mg EFV C)  75 mg EFV, D) 
100 mg EFV. 
4.3.3. Morphology of PCL-EFV NPs 
Figure 4.6 presents the SEM images of the prepared PCL-EFV NPs. All PCL-EFV 
NPs prepared in the presence of lactose showed spherical morphology. These 
results confirm the ability of lactose as a surface modifier to form spherical particles 
(Takeuchi et al). Some PCL-EFV NPs prepared in the presence of trehalose showed 
the formation of crystals, these might be due to low Tm of trehalose when compared 
to lactose. 
When the amount of EFV drug was increased from 50 mg, 75 mg to 100 mg using 
lactose and EA only, the morphology of the NPs was not affected (Fig.4.7). PCL-DF 
NPs also presented spherical morphology.  
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(E)              (F) 
Figure 4.6: SEM images: (A) PCL-EFV NPs with DCM and lactose, B) PCL-EFV NPs with EA and lactose, C) PCL-EFV  
NPs with DCM/EA and lactose, D) PCL-EFV NPs with DCM and trehalose, E) PCL-EFV NPs with EA and trehalose, f) PCL-EFV 
NPs with DCM/EA and trehalose. 
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       (C)           (D) 
Figure 4.7: SEM images when EA and lactose were used to prepare the NPs. A) PCL-DF NPs, B) PCL-EFV (50 mg) NPs C) PCL-
EFV (75 mg), D) PCL-EFV (100 mg) NPs. 
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4.3.4. Structural compositions of PCL-EFV NPs 
FTIR spectroscopic analysis was performed only on the PCL-EFV (100 mg) 
prepared with partially water soluble solvent EA and lactose as an excipient. Pure 
PCL, PCL-DF NPs, EFV drug and PCL-EFV NPs (Fig 4.8) showed the 
characteristic peak of the PCL polymer at around 1721.4 cm -1and 1725.9 cm -1 
due to the C=O stretching vibration (Wu, 2005; Sahoo et al., 2010). A peak at 
2249.1 cm -1 on the EFV drug spectrum was observed and is due to exocyclic 
triple bond stretching, a similar results was reported by (shown et al., 2010). 
Slightly small peak at 2249.0 cm-1 for PCL-EFV NPs was observed, which shows 
that the structural composition of the EFV drug was maintained. The small peak 
observed might be due to the higher EE obtained, suggesting that small amount of 
EFV drug was on the surface of the NPs.  
 
Figure 4.8: FTIR spectra of (A) Pure PCL, (B) PCL-DF NPs, (C) EFV drug, and 
(D) PCL-EFV NPs. 
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4.3.5. X-ray diffraction 
XRD analysis, shown in Fig 4.9 was used to determine the crystalline content of 
the prepared PCL-EFV (100 mg) and PCL-DF NPs. XRD diffractogram for pure 
EFV drug presented multiple peaks, showing the crystalline nature of the drug. 
The pure PCL polymer presented two sharp peaks at around 21.3o and 23.9o, 
which are due to scattering from crystalline region and the underlying “hump” 
indicated in red lines are due to scattering from the amorphous region (Young and 
Lovell, 1991), a similar spectrum was reported by (Wu, 2005) for pure PCL. 
However the XRD diffractograms for PCL-EFV (100 mg) and PCL-DF NPs were 
characterized by broad hump and the absence of any sharp peaks over the entire 
2 theta. This suggests that the prepared NPs both drug and polymer exist in an 
amorphous form. 
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Figure 4.9: X-ray diffraction patterns of (A) PCL-EFV nanoparticles, (B) PCL-DF 
nanoparticles, (C) EFV drug, and (D) pure PCL 
 
 108 
4.3.6. Thermal analysis 
The DSC curve for EFV drug (Fig.4.10) illustratess the endothermic peak in the 
range of 177.56oC (enthalpy change of 119.5 J/g), due to sample dehydration, 
which was confirmed by a weight loss of 52.78% verified in the range of 186.40oC 
to 246.58oC in the TGA curve, similar results were obtained by Sathigari et al, 
2009 ( Chapter 2) (Fig. 4.11).  
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Figure 4.10: DSC curve of EFV drug in a dynamic nitrogen atmosphere, at a 
heating rate of 10oC/min. 
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Figure 4.11: TGA curve of EFV drug in a dynamic nitrogen atmosphere, at a 
heating rate of 10oC/min. 
DSC second heat of pure PCL, PCL-DF and PCL-EFV (100 mg) NPs are 
presented in Fig 4.12. Table 4.1 summarizes the final Tm and enthalpy change of 
the obtained thermograms. PCL polymer showed the Tm of 53.4
 oC, PCL-DF and 
PCL-EFV NPs showed the Tm of 54.80
oC and 47.64oC, respectively, which are all 
nearly similar to the Tm of the pure PCL polymer (Woodruff and Hutmacher, 2010). 
Moreover the Tg of the pure PCL, PCL-DF NPs and PCL-EFV NPs was found to 
be at -60oC, similar to the reported value (Woodruff and Hutmacher, 2010). These 
results suggest that the double emulsion spray-drying method did not affect the 
melting properties of the PCL polymer. However, the enthalpy decreased 
significantly when the polymer was processed with the double emulsion spray-
drying method, and it further decreased to a lower value when the EFV was nano-
encapsulated into the polymer NPs. As shown in Fig. 4.13 no exothermic peak 
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was observed, suggesting that the entropy of the spray dried NPs was decreased. 
Decrease in entropy change of the system causes the enthalpy of the system to 
become small as shown in Fig 4.13, leading to higher values of G. The higher 
values of G cause the material to be amorphous.  
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Figure 4.12: DSC of (A) pure PCL, (B) PCL-DF NPs, and (C) PCL-EFV NPs in a 
dynamic nitrogen atmosphere, at a heating rate of10 oC/min. Second heating 
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Table 4 1: Melting and enthalpy change of PCL, PCL-DF and PCL-EFV NPs from 
DSC thermograms 
Materials Final temperature Tm (
oC) Enthalpy Change J/g 
Pure PCL 53.44 76.9 
PCL-DF 54.80 8.60 
PCL-EFV 47.64 5.25 
 
DSC cooling temperature (Fig. 4.13) for the pure PCL polymer, PCL-DF and PCL-
EFV (100 mg) NPs. In agreement with XRD diffractograms, the pure PCL polymer 
indicated the sharp exothermic peak, showing the crystalline nature of the 
polymer. However the spray dried PCL-DF and PCL-EFV (100 mg) NPs 
corresponding to the cooling temperature showed no Tc, supporting the evidence 
that our NPs might be amorphous. 
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Figure 4.13: DSC thermograms of (A) pure PCL (B) PCL-DF, and (C) PCL-EFV 
NPs in a dynamic nitrogen atmosphere, at a heating rate of 10oC/min. Cooling 
temperature. 
TGA thermograms of the pure PCL and PCL-DF and PCL-EFV (100 mg) NPs are 
presented in Fig. 4.14. TGA curve corresponding to pure PCL showed that 
polymer was thermally stable until 136.27oC.. Both PCL-DF and PCL-EFV (100 
mg) NPs showed low thermal stability when compared to the pure PCL polymer. 
This may be due to the fact that the NPs have a greater superficial area, since 
there are more reactive than the polymer; consequently the thermal decomposition 
occurs much faster (Mainardes et al, 2006). 
The residual moisture of the PCL-DF and PCL-EFV (100 mg) NPs was determined 
using TGA. The results obtained are 4.289% for PCL-DF nanoparticles and 
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4.143%, for PCL-EFV (100 mg).NPs. These results are in agreement with the 
reported values of the spray dried particles in the literature, which ranges from 2 to 
15% 
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Figure 4.14: TGA thermograms of (A) pure PCL, (B) PCL-DF and (C) PCL-EFV 
NPs. 
4.3.7. Drug release from the PCL-EFV NPs 
Figure 4.13 presents the drug release rate of the PCL-EFV (100 mg) NPs 
dispersed at various pH values i.e. 1.3, 4.4 and 6.8. The release of the EFV drug 
from the PCL NPs was found to be affected by the pH media. pH 6.8 showed the 
highest release rate, however the release was decreasing as the pH approaches 
acidic for both pH 1.3 and 4.5. This effect is due to the repulsion between H+ and 
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cations on the surface of the PCL-EFV NPs, attributed to CS. Nevertheless the 
spray dried NPs showed a sustained release for more than 5 days.  
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Figure 4.13: Drug release rate of PCL-EFV NPs. A) pH 1.3, B) pH 4.5, and C) pH 
6.8. 
4.3.8. Stability 
The dry state PCL-EFV (100 mg) NPs showed no change of the mean particle 
size, PDI, ZP and EE, when they were stored in the desiccator for 1 year. Thus the 
results indicate good physical and chemical stability of NPs. 
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4.4. Conclusions 
This work demonstrated that the double emulsion spray-drying process is a 
sufficient method to nano-encapsulate EFV into PCL polymer. The obtained PCL-
EFV NPs presented that the mean particle size and PDI were strongly affected by 
the solvent. The surface morphology was found to be affect by the excipient. The 
surface composition of the PCL-EFV NPs showed that characteristics peaks of the 
polymer and the drug were still the same even after the double emulsion spray-
drying process. The process parameters utilized in this study helped to convert the 
crystalline drug and semi-crystalline polymer into the amorphous form, without 
changing the chemical properties of the drug and the polymer. The in vitro drug 
release showed a sustained release of more than 5 days. 
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CHAPTER 5:  
CONCLUSIONS AND RECOMMENDATIONS 
 
 
 
5.1. Conclusions 
A double emulsion spray drying method was applied successfully to nano-
encapsulate LAM and EFV into PCL polymer. During the preparation of the PCL-
(LAM or EFV) NPs, various parameters affecting the mean particle size, PDI and 
zeta potential of the final product were fully characterized. The effect of the 
solvents, namely DCM, EA and their mixture were understood. The results showed 
that the partially water soluble solvent EA yielded small mean particle size and 
homogeneous NPs when compared to DCM (immiscible solvent in water), for both 
the nano-encapsulation of LAM or EFV. A similar trend was also observed when 
EA was mixed with DCM, implying that the addition of DCM in EA decreases the 
solubility of EA consequently increasing interfacial tension at the aqueous/organic 
interface. Overall zeta potential of the NPs was found to be positive and stable due 
to chitosan added on the preparation. Inclusion of chitosan on the NPs is of 
importance since it can open the tight junctions and in this way allows paracellular 
transport across the epithelium. It is reported that both  nasal  and  oral  drug 
delivery research  has  showed  that  signiﬁcantly  higher amounts of drugs  can  
be  transported after  co-administration with chitosan. Moreover it allows the NPs 
to deliver the drugs in the small intestines. The effects of excipients were also 
studied, using lactose and trehalose. The obtained results demonstrated that 
lactose was a better excipient as these yielded small mean particle size and better 
PDI. SEM images showed that some of the NPs prepared with trehalose were not 
spherical, as presented by the formation of crystals, opposes to lactose which 
showed spherical NPs in all formulations. 
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The surface composition of the PCL-(LAM or EFV) NPs showed that 
characteristics peaks of the polymer and the drugs were not affected after the 
double emulsion spray-drying process. The crystalline drugs i.e. EFV or LAM and 
semi-crystalline polymer, PCL were converted into amorphous form without 
changing the chemical properties of the drug and the polymer, as showed by the 
XRD and DSC thermograms. DSC second heating analysis showed that after 
spray drying process was carried out, the thermal integrity associated with the 
PCL polymer did not change. The moisture content of the spray dried NPs was 
found to be in the range of the values reported with the spray drying technique. 
The in vitro drug release showed a sustained release of more than 5 days when 
EFV was nano-encapsulated into PCL NPs, conversely PCL-LAM NPs showed the 
release of 24 hours. Thus with the results obtained with this study, poor solubility 
associated with EFV might be solved as the amorphous form materials has high 
solubility as compared to the crystalline ones. Patient compliance might also be 
solved since in vitro release showed the sustained release of more than 1 day for 
LAM and more than 5 days for EFV. This might completely decreases intake of 
ARVs in higher doses everyday. 
The method developed in this project does not only open a door to nano-
encapsulate ARVs with different features but can also be applied to nano-
encapsulate other hydrophilic and hydrophobic drugs for other PRDs. 
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5.2. Recommendations 
The main goal of this study was to prepare PCL-(LAM or EFV) NPs with better 
mean average particle size, homogeneous and good zeta potential. Although 
significant progress was made towards understanding the preparation method 
developed, other areas of research should be addressed before the NPs could be 
successfully translated into drug delivery applications. The future work should 
include the following: 
 Increase the EE of LAM by changing the concentration of PCL polymer in the 
organic phase and other process parameters. This might change the release of 
LAM from PCL NPs to more than 2 days. 
 Perform the solubility studies. 
 Study the oral bioavailability of the nano-encapsulated drugs. 
 Study the biodistribution of the prepared NPs upon oral administration. 
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APPENDIX 1 
 
Raw data for Figure 3.2 (including zeta potential) 
Table 1: Properties of PCL-LAM NPs (data represent mean ± SD, n = 3) 1 = DCM 
was used as solvent, 2= EA was used as a solvent, 3= mixture of DCM and EA, a 
= lactose used as a excipient, and b = trehalose used as excipients. 
Formulation Size (nm) PDI ZP (mV) 
PCL-LAM (1a) 454.4±111 0.45±0.06 +18.0±1.48 
PCL-LAM (2a) 214.7±3.05 0.23±0.01 +18.5±1.25 
PCL-LAM (3a) 552.6±8.46 0.48±0.07 +22.8±0.95 
PCL-LAM (1b) 604.3±8.46 0.47±0.07 +18.3±0.56 
PCL-LAM (2b) 277.1±27 0.42±0.04 +17.8±2.75 
PCL-LAM (3b) 566.9±47.8 0.44±0.05 +19.9±0.96 
 
Raw data for Figure 3.4 (including zeta potential) 
Table 2: Mean particle size, PDI and EE (%) of the prepared PCL-LAM NPs (data 
represent mean± SD, n = 3) 
Formulation Size (nm) PDI ZP (mV) EE (%) 
PCL-DF 233.9±3.36 0.155±0.02 +29.3±0.73 n/a 
PCL-LAM NPs(a) 243.6±3.07 0.165±0.01 +22.8±0.71 77.82±4.40 
PCL-LAM NPs(b) 252.0±5.17 0.205±0.02 +26.6±0.40 71.48±6.10 
PCL-LAM NPs(c) 214.7±3.05 0.227±0.01 +22.9±0.50 64.21±401 
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Raw data for Figure 4.2 (including zeta potential) 
Table 3 Properties of PCL-EFV nanoparticles (data represent mean ± SD, n = 3) 1 
= DCM was used as solvent, 2= EA was used as a solvent, 3= mixture of DCM 
and EA, a = lactose used as excipient, and b = trehalose used as excipient 
Formulation Size (nm) PDI ZP (mV) 
PCL-EFV (1a) 349±8.90 0.42±0.01 +18.1±1.24 
PCL-EFV (2a) 217±2.48 0.093±0.02 + 26±0.30 
PCL-EFV (3a) 393.1±13.7 0.323±0.01 +14.5±0.20 
PCL-EFV (1b) 368.2±10.7  0.379±0.05 +23.1±0.35 
PCL-EFV (2b) 247±3.20 0.125±0.05 +18±0.47 
PCL-EFV (3b) 448.4±9.03  0.470±0.01 +20±0.15 
 
Raw data for Figure 4.4 (including zeta potential) 
Table 4 : Properties of PCL-EFV nanoparticles (data represent mean ± SD, n = 
3),a) 50 mg EFV, b) 75 mg EFV and c) 100 mg EFV on the formulation 
Formulation Size (nm) PDI ZP (mV) EE (%) 
PCL-DF NPs 233.9±3.36 0.155±0.02 +29.3±0.73 n/a                 
PCL-EFV NPs(a) 238.8±1.55 0.225±0.03 +23.7±0.81 94.8±2.10 
PCL-EFV NPs(b) 207.9±2.18 0.147±0.02 +17.8±0.90 93.6±1.10 
PCL-EFV NPs(c) 217.0±2.48 0.093±0.02 +26.0±0.70 93.1±3.03 
 
 
